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Background:  Bridging the Discharge Gap Effectively (BRIDGE) is a program 
that aims to provide patients with cardiovascular disease quality evidence-based 
care through their hospital-to-home transition.  The BRIDGE nurse practitioners 
assess patients’ clinical status, make adjustments in their therapeutic regimens 
as needed, educate patients and families about health promotive activities and 
refer when necessary.  This study aimed to determine if the BRIDGE model was 
effective in improving six-month medication persistence rates (for secondary 
prevention medications), lowering 30-day hospital readmission rates, and 
reducing overall health care costs associated with readmission.   
 xiii 
Methods:  Data were collected retrospectively on all patients referred to the 
BRIDGE program.  Medication persistence was analyzed using logistic 
regression, rates were calculated for hospital readmissions, and a cost model 
was developed to compare BRIDGE costs against avoided hospital readmission 
costs.  All eligible patients referred to BRIDGE received an appointment within 14 
days of discharge.  Analyses compared attendees with non-attendees.   
Results:  Of 500 patients referred to the BRIDGE program, 74 were excluded 
due to early adverse events.  Of those remaining, 25.2% (n=107) had a 
discharge diagnosis of acute coronary syndrome (ACS), and 72.2% (70) 
attended BRIDGE.  The mean age of study participants was 62.4 years and the 
majority were female (59.8%) and white (85.6%).  With the exception of 
dyslipidemia there were no baseline differences between groups. 
 Most patients were prescribed aspirin, β-blockers, ACE-inhibitors, statins, 
and clopidogrel at discharge (range 75.0% to 97.9%) and remained on therapy at 
six months (range 80.6% to 95.5%).  There were no differences in persistence 
rates between groups.  BRIDGE participants had lower readmission rates at 30 
(9.7 vs. 27.8. p=.112), 60 (11.3 vs. 38.9, p=.012), 90 (16.1 vs. 38.9, p=.052), and 
180 (27.4 vs. 50, p=0.72) days post-discharge.  On average, the program saved 
$4,944 per-patient or $306,537 overall in avoided readmissions.  Conclusion:  
Most ACS patients require early post-discharge follow-up. BRIDGE fulfills this 
need with demonstrated success in reducing 30-day readmissions at a cost 
value.  The BRIDGE model is thus a novel and practical approach to addressing 
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transitional care and the vexing nation-wide problem of hospital readmissions for 












CHAPTER I  
INTRODUCTION 
 
Nearly 20% of all patients discharged after an acute myocardial infarction 
(AMI) will have a rehospitalization within 30 days (Krumholz et al., 2009).  Half of 
those rehospitalized patients will have had no contact with a healthcare provider 
since their discharge (Jencks, Williams, & Coleman, 2009). This rate of AMI 
readmissions exceeds the median rate for all disease readmissions in the United 
States (Jencks et al., 2009).  Data from the Medicare Provider Analysis and 
Review (MEDPAR) database found that 34% of hospital discharged Medicare 
beneficiaries between 2003 and 2004 were rehospitalized within 60 days of 
discharge and 68.9% were either readmitted or dead within one year (Jencks et 
al., 2009; Krumholz et al., 2009).  The cost of these unexpected readmissions 
exceeded 17 billion dollars in 2004 (Jencks et al., 2009; Krumholz et al., 2009), 
representing a significant burden for rising healthcare costs.  In response to this 
trend, legislation has been proposed to reduce insurance reimbursement to 
hospitals for readmission services (Jencks et al., 2009).   
Exactly what circumstances lead to readmissions following an AMI are 
unclear, although causal speculations include early discharge, insufficient 
discharge education, poor patient comprehension (Greenwald & Jack, 2009), a 
shortage of cardiologists (Fye, 2004), and lack of adherence to joint American 
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Heart Association/American College of Cardiology secondary prevention 
guidelines (Eagle, Kline-Rogers, et al., 2004; Mehta et al., 2002). Efforts to 
remedy these potential readmission contributors have looked at a variety of care 
models as possible mediators.  The current focus is on the transitional phase of 
care between discharge and outpatient follow-up.  These models have the 
potential to revolutionize our current care delivery system by elevating 
transitional care beyond conceptualization to an integral component in the 
continuum between acute and ambulatory care.  Though most research in this 
area has focused on heart failure, a few studies have addressed acute coronary 
syndrome (ACS); the broader definition of coronary disease that includes AMI 
and unstable angina (see Appendix).  To date however, no single intervention 
has been successful enough to be adopted by the greater healthcare industry 
(Jencks et al., 2009).   
 In 2007, the University of Michigan Health System (UMHS) responded to 
the problems identified in the hospital-to-home transition by developing the 
Bridging the Discharge Gap Effectively program (BRIDGE).  The BRIDGE 
program was designed to provide seamless care to all patients discharged from 
the UMHS after experiencing an ACS event.  The main goals of BRIDGE were 
aimed at promoting compliance with evidence based therapies, improving patient 
outcomes, and decreasing readmissions (Housholder & Norville, 2009).  Now 
reaching its five-year anniversary, the BRIDGE program is poised to evaluate its 
efficacy in achieving its aims. 
 3 
Gaps in the Literature 
 Although currently receiving much attention, transitional care models and 
their outcomes remain in an early stage of research development.  A literature 
search of “transitional care” through MEDLINE and CINAHL 2006-2011, 
restricted to the English language and its care of individuals over 45 years of 
age, returned only 35 articles.  After excluding articles that were not from the 
United States or related specifically to the hospital-to-home transition, 11 articles 
remained.  Of these remaining articles, there was one randomized controlled 
trial, one cross-sectional study, one qualitative study, two literature reviews, two 
general articles, and four case studies.  This type of distribution in the level of 
evidence is common in the early stages of concept development.  Broadening 
the search criteria to span the last decade and including terms such as 
“discharge planning” and “care coordination,” returned a slightly larger number of 
studies and reviews, though not consistently specific to transitional care, and 
most reviews only cited a small number of studies including:  Bodenheimer 
(2008), Brooten et al. (2002), Chiu and Newcomer (2007), Jacob and Poletick 
(2008), Naylor and Keating (2008), and Phillips et al. (2004). 
 Of the more broadened search for studies of transitional care, patients 
over 60 years of age were primarily targeted (Coleman, Parry, Chalmers, & Min, 
2006; Naylor et al., 1994; Naylor et al., 1999; Phillips et al., 2004; Sinclair, 
Conroy, Davies, & Bayer, 2005) and these studies often failed to address racial 
or cultural variations in care outcomes.  The majority of those using randomized 
controlled trials emphasized a limited number of chronic diagnoses such as 
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stroke, heart failure and ACS (Coleman et al., 2006; Harrison et al., 2002; Kind, 
Smith, Frytak, & Finch, 2007; Naylor et al., 2004; Phillips et al., 2004; Sinclair et 
al., 2005).  Indeed, only four trials included AMI (Naylor, et al., 1994; Naylor, et 
al., 1999; Stewart & Horowitz, 2002), and in only one of these (Sinclair et al., 
2005) was it the primary focus.  For the most part, heart failure is the leading 
diagnosis for research in this area.  Several of the reviews discuss patient 
adherence to therapeutic regimens as part of the success in maintaining health 
and avoiding hospital readmission, but surprisingly few actually measure 
adherence (Peikes, Chen, Schore, & Brown, 2009). The primary outcome 
measure attributed to successful transitional care is the rate of hospital 
readmission (Coleman, Parry, Chalmers, & Min, 2006; Krumholz, et al., 2002; 
Naylor, et al., 2004; Naylor, et al., 1999; Peikes, et al., 2009; Sinclair, et al., 
2005; Stewart, Pearson, Luke, & Horowitz, 1998).  Thus, while these studies 
provide important data supporting transitional care as a potential mediator, there 
remain salient questions.  For example, the concept of dose is lacking throughout 
the literature.  That is, no study has evaluated the amount of transitional care 
interaction required to achieve any given outcome. Perhaps more important is 
that fewer than half of the studies in the last decade (and only one in the last five 
years) provide analyses of comprehensive cost data (Chiu & Newcomer, 2007).  
This is particularly relevant in an era of escalating health care costs and rising 
numbers of older adults who may need these services.  Thus, this study aims to 
address the latter gap by assessing differences in six-month medication 
persistence rates (for secondary prevention medications), 30-day readmission 
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rates, and to compare costs between patients who participated in the transitional 
care BRIDGE program and those who received usual care following hospital 
discharge for an acute coronary event.  Each of these topics will be addressed 
separately in chapters 2, 3, and 4. 
Specific Aims and Research Hypotheses 
The specific aims and hypotheses of this study are: 
1) To determine if there is a difference in six-month medication persistence rates 
(beta-adrenergic blocking agents [ß-blockers], angiotensin converting enzyme 
inhibitors [ACE-inhibitors] or angiotensin receptor blocking agents [ARBs] in 
patients intolerant to ACE-inhibitors, aspirin, HMG-CoA reductase inhibitors 
[statins], and clopidogrel) following discharge from the hospital for an ACS 
event between patients who participated in the nurse practitioner (NP)-
delivered BRIDGE program and those who did not. 
H1.1: Compared with patients who had usual care, patients who 
participated in the BRIDGE program will have higher medication 
persistence rates six months after discharge. 
2) To determine if there is a difference in hospital readmissions following 
discharge from the hospital for an ACS event between patients who 
participated in the NP-delivered BRIDGE program and those who did not. 
H2.1: Compared with patients who had usual care, patients who 
participate in the BRIDGE program will have a lower 30-day hospital 
readmission rate. 
 6 
3) To determine costs associated with the BRIDGE model and the difference in 
costs associated with its use compared to nonuse (usual care) in hospital 
readmissions following discharge from the hospital for an ACS event. 
H 3.1: Compared with usual care, there will be a cost reduction for care 
associated with participation in the BRIDGE program. 
These aims are addressed in 3 papers as follows:  Aim 1 in Paper one 
(chapter 2); aim 2 in Paper two (chapter 3); and aim 3 in paper three (chapter 
4). 
Background and Significance 
Acute Coronary Syndrome 
 Cardiovascular disease is the leading cause of death in the United States 
(U.S.).  Indeed, more than a half million Americans die each year from coronary 
heart disease (CHD) alone, making deaths from CHD more prevalent than any 
other single illness (American Heart Association, 2009; Rosamond et al., 2007).  
Data from the American Heart Association (AHA) estimates that the incidence of 
acute myocardial infarctions in adults over 20 years of age will reach 785,000 this 
year and will cost an estimated 160 billion dollars in both direct and indirect 
expenses (AHA). 
 Despite the urgent nature of acute coronary syndrome (ACS), the event 
may be considered purely an exacerbation of underlying chronic CHD.  There is 
a 53% likelihood that patients will experience more than one ACS event (AHA, 
2009).  However, with early treatment and adherence to evidence-based 
guidelines, both morbidity and mortality are reduced (Antman et al., 2004).  As 
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part of the IMPACT study, Ford et al. (2007) estimated that risk factor 
management alone (reducing lipids, glucose, and blood pressure; eliminating 
smoking; and, increasing physical activity) could reduce AMI mortality by as 
much as 44%. 
American College of Cardiology/American Heart Association ACS 
Guidelines 
 Since 1980, the American College of Cardiology (ACC) and the American 
Heart Association (AHA) have collaboratively produced and revised guidelines 
for the prevention, diagnosis, and management of a variety of cardiovascular 
diseases (CVDs).  The ACC/AHA Task Force consists of cardiology experts and 
representatives from other medical and specialty groups.  Its intent is to give 
healthcare providers a tool to support evidence-based clinical decision-making.  
The guidelines offer a range of acceptable approaches from a consensus of 
experts, but should not replace the clinical judgment of the primary care provider 
(Antman et al., 2004) 
 The process of ACC/AHA guideline development involved a 
comprehensive literature review, weighing of the evidence, and estimation of 
outcomes based on patient modifiers (Antman et al., 2004). All evidence is 
graded according to the Classification and Recommendations and Level of 
Evidence rubric.  This rubric first identifies the class of data according to the 
degree that the benefits outweigh the risks, or vice versa (Class I: Benefit >>> 
Risk and are recommended, Class IIa: Benefit >> Risk and are reasonable, 
Class IIb: Benefit > Risk and may be useful, and Class III: Risk > Benefit and are 
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not recommended).  Within each of the four classifications, the quality of the 
evidence is evaluated according to three possible rankings (Level A: data from 
multiple randomized clinical trials or meta-analyses; Level B: data from a single 
randomized trial or nonrandomized studies; Level C:  consensus opinions of 
experts, case studies, or standard-of-care documents).  This grading scheme 
enables estimations of the size and certainty of treatment effects when caring for 
patients with ACS (Antman et al., 2004).   
 The initial ACC/AHA Task Force guidelines for ACS were presented in 
1990 and were focused solely on the early management of AMI.  Since 1990, 
there have been nine revisions or updates to this original document.  The most 
recent publications related to ACS are the “2011 ACCF/AHA Focused Update 
Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients 
With Unstable Angina/Non-ST-Elevation Myocardial Infarction” (Anderson et al., 
2011) and the “AHA/ACC Guidelines for Secondary Prevention for Patients With 
Coronary and Other Atherosclerotic Vascular Disease: 2006 Update”  (Smith et 
al., 2011).  This latter revision reflects the evolution of AMI management from 
acute management to preventative and long-term treatment strategies and 
makes secondary prevention recommendations including short-term discharge 
goals, medication considerations, and long-term lifestyle modification.  The 
transition from hospital-to-home, medication management and discharge 
education are identified as key components in patients’ successful recovery from 
AMI.   
 9 
Discharge goals for ACS patients thus include increasing patient and 
family education about the disease and treatment, need for appropriate follow-up, 
timing of the proposed follow-up, and suggested lifestyle modifications (Antman 
et al., 2009).  Patients must be educated about their diagnosis, prognosis, and 
management in order for them to understand their role in minimizing future 
events.  Additional education is necessary to support lifestyle modifications 
related to diet, smoking cessation and increased physical activity.  Because of 
the relationships between CHD and hyperlipidemia and between hypertension, 
and hypercoagulation, education about the use of aspirin, β-blockers, ACE-
inhibitors and statins for secondary prevention of ACS events is critical.  Lastly, 
patients must understand why follow-up is important, what occurs during follow-
up, and with whom the follow-up should take place.  Given that the average 
length of stay for an ACS event is under 6 days (Spencer, Lessard, Gore, 
Yarzebski, & Goldberg, 2004), it is little wonder that patients may not be able to 
absorb this tremendous amount of information during this short convalescent 
phase.  Thus, these interventions should be assessed soon after discharge to 
improve guideline adherence rates for patients, clinicians, and institutions during 
the hospital-to-home transition (Ellerbeck et al., 1995; McLaughlin et al., 1996; 
Mehta et al., 2002).  
Medication Adherence and Persistence 
Medication adherence is a substantial and ongoing problem in healthcare 
(DiMatteo, 2004).  Poor adherence is associated with increases in morbidity, 
mortality, rehospitalizations, and overall health care costs (Sokol, McGuigan, 
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Verbrugge, & Epstein, 2005). Medication adherence, also known as compliance, 
is a measure of “the extent to which a patient acts in accordance with the 
prescribed interval and dose of a dosing regimen” over a period of time and is 
often reported as a percentage (Cramer, Roy, Burrell, & Fairchild, 2008, p. 46).  
In contrast, medication persistence is defined as “the duration of time from 
initiation to discontinuation of therapy.  Continuing to take any amount of the 
medication is consistent with the definition of persistence” (Cramer et al., 2008, 
p. 46). Both medication adherence and persistence are essential for obtaining the 
therapeutic benefits observed in clinical trials (Choudhry & Winkelmayer, 2008).  
However, without persistence, adherence is moot.  In fact, life-long persistence 
for many chronic conditions is essential for prevention of secondary events. 
Medication persistence with a regimen of aspirin, ß-blockers, ACE-
inhibitors, statins, and clopidogrel has proven essential for preventing 
reoccurrence and progression of coronary disease in ACS patients (Antman et 
al., 2009).  Poor medication persistence is associated with an increased risk of 
mortality (Ho, Spertus, Masoudi, & Reid, 2006). The largest decline in 
persistence with cardioprotective therapies has been observed within the first 
month after discharge from an ACS event (Ho et al., 2006) and less than 50% of 
patients remain on therapy at two years (Akincigil et al., 2008; World Health 
Organization, 2010).   
The economic impact of persistence (and rates of adherence) across a 
number of health conditions is well documented (Sokol et al., 2005; World Health 
Organization, 2010).  Among diabetic and hypercholesterolemic patients, 
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adherence with combination therapy is associated with lower healthcare costs 
(Sokol et al., 2005).  In fact, medication costs are completely offset by the 
reduction in medical costs for these patients.  Higher rates of adherence are also 
associated with lower hospitalization rates and lower costs for hospitalization 
among patients with hypertension, congestive heart failure, diabetes, 
dyslipidemia, and post-AMI (Choudhry, Patrick, Antman, Avorn, & Shrank, 2008; 
Sokol et al., 2005). 
Hospital Readmissions 
 As noted earlier, hospital readmissions are a major problem in the United 
States.  Almost one fifth (19.6%) of the 11,855,702 Medicare beneficiaries’ (who 
constitute the largest number of AMI patients) discharged from hospitals in 2003-
2004, were readmitted within 30 days (Jencks et al., 2009).  According to 
Krumholz, et al. (2009), hospital readmission statistics reported for CVD up to 
five years later were even worse (ACS M=19.9%, range 15.3% to 29.4%; heart 
failure M=24.4%, range 15.9% to 34.4%).   
 Hospital readmissions are a problem when considered from multiple 
perspectives.  From an individual or patient perspective, readmissions mean that 
the patient is sicker.  Rehospitalized patients spend more time away from home 
and work than those who remain in the community; they consequently suffer 
more social isolation, lost wages, and increased expenses.  From a social 
standpoint, readmissions affect families, communities, and the work force and 
are an added burden to the overall healthcare system.  From an institutional or 
health systems perspective, hospital readmissions present a two-sided issue: 
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filling hospital beds generates revenue; however, filling those hospital beds with 
readmissions suggests a poor quality of care that from a marketing standpoint (to 
consumers and insurers) may outweigh the benefit of any financial remuneration 
from these readmissions. 
 The perspective of this dissertation, supported by several new policy 
initiatives, is that lower hospital readmissions are generally accepted as a 
positive and desirable outcome.  In June 2009, Mary Naylor, PhD RN, Professor 
of Gerontology and Director of the New Courtland Center for Transitions and 
Health at the University of Pennsylvania, proposed the Transitional Care 
Reimbursement Bill (H.R. 2773 and S. 1295) with the aim of preventing or 
reducing hospital readmissions.  Recognizing the potential impact of the recent 
trend toward decreased Medicare reimbursement for home care services, this bill 
provided reimbursement for services aimed at preventing readmissions through 
more comprehensive care during the hospital-to-home phase.  Naylor's proposed 
bill followed Peter Orszag's (then Director of the Office of Management and 
Budget) March 3, 2009 testimony to the House of Representatives Committee on 
Budget for a proposed bundled payment policy that would create a single 
payment for hospitalization and post-acute care, with penalties in the form of 
reduced reimbursement for hospital readmissions in centers with higher rates.  
Orszag proposed that this would result in a $26 billion dollar savings to Medicare 
over a ten year span (Orszag Testimony, President's Fiscal Year 2010 Budget, 
2009).   
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 In response to the financial implications, quality concerns, and public 
reporting of discharge planning and readmission rates, many researchers and 
institutions have explored the phenomenon of hospital readmissions and why 
they occur (Arora & Farnan, 2008; Cumbler, Carter, & Kutner, 2008; Greenwald 
& Jack, 2009; Jacob & Poletick, 2008).  Data show that rehospitalizations occur 
primarily because patients decompensate after discharge and that this 
progressive decline is the result of a multifaceted interaction between client, 
discharging hospital, and outpatient follow-up (Cumbler et al., 2008; Greenwald & 
Jack, 2009; Jacob & Poletick, 2008).  Examining these three areas during 
patients' transition from hospital-to-home is thus critical if appropriate 
interventions are to be developed to decrease hospital readmissions.   
 One such intervention is the national Hospital to Home (H2H) program. 
Championed by the American College of Cardiology Foundation and the Institute 
for Healthcare Improvement, H2H is modeled after the successful Door to 
Balloon (D2B) program that aimed to reduce the amount of time patients with ST-
segment elevated myocardial infarctions waited for intervention after arriving at 
the hospital.  The goal of the H2H program is to reduce readmission rates among 
patients discharged with heart failure or acute myocardial infarction by 20% by 
2012 (Brindis & Krumholz, 2010) using three guiding principles: that patients 
adhere to their medications; that patients receive early post-discharge follow-up; 
and, that patients understand when and who to call for help (Brindis & Krumholz, 
2010).  By elevating transitional care beyond conceptualization to an integral 
component in the care continuum between acute and ambulatory care, there is 
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opportunity to improve health care delivery and patient care quality while 
achieving the national goal of reducing hospital readmission rates.   
Cost and Cost Effectiveness Analyses in Acute Coronary Syndrome 
 While most experts may agree that transitional care is an essential 
component of providing high quality care, data to support the cost of providing 
transitional care and improving patient adherence to secondary prevention 
therapies to reduce adverse outcomes is still needed.  How best to approach 
measures of cost and quality is also under study.   
 A traditional cost analysis describes the tangible costs of programs and 
their operating costs.  These costs are often compared to a standard (i.e. usual 
care) as a means to justify or determine the utility of one program over another 
(Warner & Luce, 1982).  To make such a comparison, it is essential that 
equivalent data be examined.  For example, in accounting for provider salary in 
one program, one must determine whether this rate represents salary only or 
salary plus benefits.  When considering overhead, one must be clear whether to 
include cleaning, maintenance and upkeep, or only rent.  In the absence of such 
detail, it is impossible to accurately compare the costs or savings across different 
programs.   
Across the literature reviewed, there was no consistent methodology for 
determining programmatic costs associated with transitional care (Coleman et 
al., 2006; Krumholz et al., 2002; Naylor et al., 2004; Naylor et al., 1994; Naylor et 
al., 1999; Stewart, Pearson, Luke, & Horowitz, 1998) .  Regrettably, this prohibits 
cost comparisons across various study designs.  Of the four studies that provided 
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enough detailed methodology to enable comparisons (Krumholz, et al., 2002; 
Naylor, et al., 2004; Naylor, et al., 1994; Peikes, et al., 2009) all report a savings 
or the potential to lower cost over usual care.  However, as a result this lack of 
standard approach, little is truly known about the cost or cost per dose of current 
transitional care models; there are no studies in the published literature that 
present data related to the cost effectiveness of transitional care.  Those that do 
purport to analyze cost are not always rigorous or generalizable. 
 In an attempt to address patient readiness for discharge for example, 
Newby et al. (2000) assessed the cost effectiveness of adding an additional day 
to each hospital stay for AMI patients to allow further convalescence and permit 
time for more detailed education.  The authors concluded that hospitalizations 
longer than three days were not economical.  It should come as no surprise that 
keeping a patient in the hospital for rest and education lacks economic appeal.  
In addition, longer hospital stays potentially expose patients to iatrogenic 
problems such as hospital-acquired infections. 
 Post-discharge interventions, on the other hand, have been more 
successful in demonstrating benefit.  Many of these interventions (Naylor et al., 
2004; Sinclair et al., 2005; Stewart et al., 1998) employed nurse practitioners to 
do post-hospital discharge home visits ranging from 1-8 times over as much as a 
three month period and concluded that this level of care was beneficial and 
reduced costs.  There is a wealth of evidence that supports the high quality of 
care and the cost effectiveness provided by advanced practice nurse models of 
care (Brown & Grimes, 1995; Horrocks, Anderson, & Sallisbury, 2002).  These 
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home-based nurse practitioner interventions provided the ideal level of care 
necessary for successful transitions.  However, these programs are not always 
feasible and cannot easily be generalized because they are resource intensive.  
Nevertheless, the cost analysis provided by Naylor et al. offers strong support for 
the utilization of such advanced practice models in transitional care.   
Theoretical Framework 
Transitional Theory and Practice 
 Transitional theory was introduced as a concept in nursing by Chick and 
Meleis (1986) in their landmark paper “Transitions: A Nursing Concern.”  Defining 
transition as change over time and “periods in between stable states” (p. 238), 
the authors then linked transitions related to health or illness as areas of nursing 
concern.  A more modern perspective suggests that when transitions are related 
to health, illness, or behavioral responses to either health or illness, they fall 
under the broader care of a health care team.  These responses fall into four 
separate transition typologies:  developmental, situational, health-illness, and 
organizational (Schumacher & Meleis, 1994).  
 Each of the four transitions has unique attributes that require different 
units of measurement and models.  Developmental transitions are individual level 
transitions such as becoming a parent, going through adolescence, or reaching 
menopause.  Situational transitions may be cognitive, such as a role or career 
change, or physical such as moving or becoming homeless.  Health-illness 
related transitions might also be cognitive or physical, such as representing an 
individual’s experience with development, living with a chronic disease, or 
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movement within levels of a health care system (ICU to general medicine, or 
hospital-to-home).  Organizational transitions are largely related to the overriding 
forces that dictate organizational change (i.e., economics, legislation, society).  
These transitions may occur in succession or simultaneously, adding to the 
complexity of the process.  
 Bridges (2004) describes a transition as an "ending, then a beginning, and 
an important empty or fallow time in between” (p. 17).  This definition suitably 
defines the health-illness related transition from hospital-to-home.  The acute 
hospitalization phase is ending, and a new at-home recovery phase is beginning.  
This transitional period can be broadly defined as the period between when a 
patient becomes aware that they will be discharged and when their care is 
successfully transferred to outpatient healthcare providers (Arora & Farnan, 
2008).  The empty time in between these points, however, is a time when many 
things can go wrong that may lead to hospital readmission or mortality (Arora & 
Farnan, 2008; Chiu & Newcomer, 2007; Cumbler et al., 2008; Greenwald & Jack, 
2009; Jacob & Poletick, 2008; Naylor et al., 2004; Phillips et al., 2004; Sinclair et 
al., 2005; Stewart et al., 1998). 
 Greenwald and Jack (2009) identified pitfalls leading to hospital 
readmission or mortality during the hospital-to-home transition as system flaws, 
patient-related issues, and/or clinician-related issues.  System problems include 
failures in communication, lack of patient education, medication errors, and poor 
follow-up planning such that patients may not learn the material they were taught, 
may not adhere to their medication regimen, or may not keep follow-up 
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appointments.  Patient-related issues pertain to the physical condition of the 
patient who may develop new problems or post-discharge complications.  
Clinician-specific errors include failing to order or follow-up laboratory tests, 
discharging patients inappropriately, failing to prescribe evidence-based 
medications, and/or neglecting to order supportive home care services.  
Intervening to ameliorate these pitfalls during this period has demonstrated a 
benefit in lowering readmission rates and improving health related quality 
measures (Chiu & Newcomer, 2007; Naylor et al., 2004).  
 Unfortunately, because of decreasing lengths of hospital stays, (Spencer 
et al., 2004), it is now increasingly difficult to ensure the quality of discharge 
education and the patients' ability to retain that information (Arora & Farnan, 
2008). This is particularly notable given that high quality discharge education is 
the strongest predictor for discharge readiness and low quality discharge 
education for hospital readmissions (Weiss et al., 2007).  Because there is often 
more than one individual responsible for overseeing this process, it is 
understandable that errors and omissions are made (Arora & Farnan, 2008).  To 
make matters worse, ACS patients are often unable to be seen by their 
cardiologists within the recommended 2-4 week period after discharge 
(Housholder & Norville, 2009).  As a result, common mistakes and 
decompensating patients are not captured in the system soon enough to correct 
and avoid further morbidity and readmission. 
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Transitional Care Models 
 As a result of the national focus on hospital readmissions, an abundance 
of transitional programs are now being piloted.  According to the Agency for 
Healthcare Research and Quality (2010), between 250 and 400 hospitals are 
now engaged in some form of readmission-reducing effort.  It should be noted 
however, that programs to reduce readmissions are not new.  More than two 
decades ago, Brooten et al. (1988) introduced a model for transitioning low birth 
weight infants from the hospital to home.  Naylor and colleagues (2004; 1994; 
1999) expanded on this model and have devoted their careers to developing and 
testing a transitional care model for older adults with chronic disease.  This 
model, the Transitional Care Model, is widely recognized and has even been 
adopted by such large care providers as Kaiser Permanente, Aetna, and the 
University of Pennsylvania Health System.  Like Brooten’s model before it, it is a 
comprehensive program that extends patient care from hospital discharge into 
the patient’s home in an attempt to facilitate a healthy transition across the 
hospital-to-home continuum. 
 Unlike Brooten (1988) and Naylor’s (1994;1999;2004) models, the vast 
majority of transitional models today tend to be more narrowly focused on pre-
discharge inpatient education and post-discharge telephone follow-up or in-home 
visits (Coleman et al., 2006; Sinclair et al., 2005; Stewart et al., 1998).  Trained 
nurses or nurse practitioners carry out many of these home-based interventions.  
In their review of various transitional care models, Phillips et al. (2004) concluded 
that programs offering both pre and post discharge support could lower hospital 
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readmissions and costs, while Jacob and Poletick (2008) concluded that low 
levels of social-support and self-confidence in ability to manage ones’ own care 
needs were the strongest predictors of readmission.   
 The hospital-to-home transition is a complex health-illness transition 
(Schumacher & Meleis, 1994) with a host of variables across multiple domains.  
In fact, a successful transition from hospital-to-home requires concurrent 
transitions in individuals and the system and how they intersect.  The complexity 
of this transition is evidenced by the lack of a theoretical framework that depicts 
the simultaneous interaction between individuals, systems, and processes.  
Instead, we have relied on various models to piece together the complex 
phenomena of transitional care.  The Quality Cost Model used in    
Naylor and Brooten’s works (Brooten et al., 1988; Brooten et al., 2002; Naylor et 
al., 2004) and the Maintaining Hope in Transition Model proposed more recently 
by Davidson, Dracup, Phillips, Padilla, and Daly (2007), are examples of 
theoretical frameworks that incorporate multiple domains.  The Quality Cost 
Model incorporates the domains of quality of care, patient satisfaction, and cost 
(Brooten et al., 2002).  The main constructs of the Maintaining Hope in Transition 
model are the individual, social relationships, and organizational plus societal 
factors (Davidson et al., 2007). While both models are well grounded and can be 
operationalized, neither fully captures the dynamic relationships that exist 
between the system, the client, and the clinician.  The Quality Cost Model lacks 
system accountability and patient variability, while the Maintaining Hope in 
Transition model fails to address clinician responsibility. 
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 As a result of the overarching systems’ influence on transitional care, 
other proposed models are largely Donabedian (1966) in nature or are more 
modern adaptations of this work from Holzemer and Reilly (1995) and Mitchell, 
Ferketich, and Jennings (1998). These models, along with the Dartmouth Clinical 
Compass (Speroff, Miles, & Mathews, 1998), are appealing because they 
integrate systems and process into the care equation.  The Donabedian Quality 
Care Outcomes Model (Mitchell & Lang, 2004) and the Outcomes Model for 
Health Care Research (Holzemer & Reilly, 1995) are both well validated in the 
literature. Yet applying these models to transitional care sacrifices the behavioral 
attributes of the individual that are paramount to a successful transition from 
hospital to home. 
If one combines all of the necessary components of a successful hospital-
to-home transition, it becomes evident that there is no simple representation, and 
that possibly no single model can fully explain the entire course.  First, any 
transitional care model must be dynamic with all constructs interrelated.  Second, 
a transitional care model cannot exist in a time vacuum.  That is, systems, 
processes, and even patients are affected by external influences that may alter 
the necessary constructs in today’s model.  Therefore, any transitional model 
must exhibit plasticity, or the ability to evolve as systems, clinicians, evidence-
based practice, policies, economics, and individuals change over time.  Finally, 
the model must incorporate both individual and organizational behaviors and 
structures. This dissertation offers the Integrated Client-Focused Transitional 
Care Model as one means to portray these constructs and their relationships. 
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The Integrated Client-Focused Transitional Care Model  
 Combining elements of Donabedian (1966), Mitchell, Ferketich, and 
Jennings (1998) and Meleis, Sawyer, Im, Hilfinger Messias, and Schumacher 
(2000), this study offers the Integrated Client-Focused Transitional Care Model 
(see Figure 1) as a framework  for studying the hospital-to-home transition.  This 
model represents the dynamic integration of individual behavior and systems 
theory as well as discussions from experts in the field.  The major concepts work 
together to simultaneously influence health outcomes.  The resulting outcomes 
reciprocally influence ongoing quality improvement efforts.  The Integrated Client-
Focused Transitional Care Model was synthesized using Walker and Avant’s 
methods for theory development (2005).  As seen in the following depiction of the 
model (Figure 1), the major concepts are system, clinician, client characteristics, 
and outcomes.  These concepts are in a dynamic relationship in which specific 
system and clinician characteristics mediate client behavior and outcomes.  The 
arrow depicts the trajectory of these interactions at work aimed toward a bullseye 
whose center reflects more desirable patient outcomes from the hospital-to-home 
transition.  When the system, clinician and client are aligned, the arrow 
(trajectory) meets with positive outcomes; when one or more misalign, the arrow 
changes course to the outer-ring of the bullseye, with negative outcomes.  One 
can easily appreciate, due to the multiple factors influencing each area, that any 
small deviation in the system, clinician, or client interaction may have potentially 
devastating outcomes.  Maintaining balance is thus a critical element in each of 




 System.  System characteristics are traditionally structural and, as 
Mitchell, et al. (1998, p. 43) define, "have the right things” in place to promote 
system stability and function .  Within the Integrated Client-Focused Transitional 
Care Model, using the BRIDGE model as an example, structural components 
include facilities, staff, instruments, technology, communication, and ancillary 
care services across the care continuum.  Ancillary care services include 
inpatient consultations from specialists (i.e. cardiology) and outpatient primary 
and specialty care providers.  While not all institutions participate in both inpatient 










































































































Figure 1.  The Integrated Client-Focused Transitional Care Model, by Sherry M. 
Bumpus, 2012 
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network for providing post-discharge referrals and protocols for communicating 
with the outpatient providers.  Less physical attributes of the system include the 
institution’s policies, values, beliefs, and programs.  For example, institutions 
promoting evidence-based practice (both as a policy and as a belief) should have 
a system for providing continuing education to their clinicians and for 
disseminating best-practice models throughout the facility.  The “Get with the 
Guidelines” program is an example of a tool kit designed for institution-wide 
application and dissemination of the joint ACC/AHA ACS guidelines.  Similarly, 
institutions supporting patient education must supply materials, information 
technology, and staff to deliver the education.  Some structures are less obvious 
than others.  For example, hospital lengths of stay may be shorter than 
necessary for optimal transition success due to the constrictions of economics, 
reimbursement, and/or external system policies that occur behind the scene.  
 Clinician.  The clinician is ultimately responsible for providing direct care 
to the acute and recovering patient (depending on where one is in the 
continuum).  The beliefs, knowledge, training, and skill of providers, together with 
their utilization of available tools and policies of the environment in which they 
practice, will mediate patient outcomes. The clinician in this regard represents 
processes.  A skilled clinician utilizing evidence-based guidelines is responsible 
for treating a patient to the point of discharge and thus is capable of evaluating 
when discharge is appropriate.  This assumes that the beliefs of the clinician are 
in agreement with standardized guidelines.  As guidelines for many conditions, 
including ACS, specify discharge education, the clinician is responsible for 
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ensuring that appropriate education has been delivered and received, whether he 
provides the education himself or delegates the task to others.  However, simply 
caring for, educating and discharging the patient does not guarantee a 
successful transition.  The clinician also has the added responsibility of ensuring 
that the patient has everything needed for a successful transition to home, 
including that secondary prevention medications have been prescribed, that the 
patient can obtain them, and that the medications are appropriate.  It also 
requires that appropriate diagnostics have been ordered post-discharge, that 
prompt follow-up has been scheduled, and that the patient’s capacity for self-care 
has been assessed.  Prompt discharge follow-up requires an outpatient referral 
and assurance that this occurs within the recommended 2-week window for ACS 
patients.  Making a referral requires that the clinician documents the stay in a 
timely manner and assures that the documentation is forwarded to outside 
providers. 
 Client characteristics.  The single most important driver of the Integrated 
Client-Focused Transitional Care Model, as the name suggests, is the client, as 
certainly there would be no need for transitional care without a person in need.  
Indeed, it is the client and his/her non-modifiable and modifiable characteristics 
that create the greatest variance in meeting positive outcomes.   
 Non-modifiable client characteristics include demographic data such as 
age, sex, race, and socioeconomic status.  The impact of the overall level of 
health of an individual and the severity of his event must also be taken under 
consideration.  In a case where two patients have a similar ACS event, if Patient 
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A also has diabetes, high blood pressure, high cholesterol, depression, and 
osteoarthritis and Patient B has no other health conditions, then, as clinicians, we 
can predict that Patient A is at a higher risk for a secondary event.  Alternatively, 
if both Patient A and Patient B were otherwise healthy with no comorbid 
conditions, but Patient A’s ejection fraction was 20% and Patient B’s was 55% 
after their events, we could predict that Patient A would do worse. The 
assessment of non-modifiable client factors must therefore include quantifiable 
measures of the client's overall level of health, comorbidities, and the severity of 
the event(s).  
 Modifiable characteristics represent the patient’s variable response to 
treatment and include client adoption of attitudes, beliefs, behaviors, and lifestyle 
modification known to reduce secondary events.  Given a client's overall health 
and the severity of his event, even under the ideal circumstances of a 
hypothetical world in which everything is done correctly every time, there will still 
be variability in treatment response.   
 Indeed, ensuring outcomes consistent with published results relies heavily 
on patient adherence behavior.  Patients who believe in their treatment and their 
ability to adhere with the treatment over time are more likely to achieve the 
desired benefits of risk reduction and health promotion.  A number of individual 
health behavior models such as the Health Belief Model (Rosenstock, 1974), 
Health Promotion Model (Pender, Murdaugh, & Parsons, 2006), Information-
Motivation-Behavioral Skills Model (Fisher & Fisher, 2002), and Theory of 
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Reasoned Action/Planned Behavior (Fishbein & Ajzen, 1975) support the 
influence of clinicians in facilitating change in client health behaviors.   
 Each health behavior model uniquely defines its own operational variables 
and measurable outcomes.  The particular variables relevant to the ACS  
population are perceived risk, perceived barriers, perceived benefit, social 
support, knowledge, attitudes, and beliefs.  Examples of measurable outcomes 
are medication adherence, the percentage of follow-up appointments kept, and 
rates of adherence to specific lifestyle modifications (i.e. smoking cessation).  
More cognitive measures may include measures of knowledge, attitudes, and 
beliefs.  Each disease state, population, and intervention may require 
conceptualization and operationalization specific to the area of study. 
 Outcomes.  The primary outcome of the Integrated Client-Focused 
Transitional Care Model is a successful transition marked by a patient’s ability to 
stay home, recover and rehabilitate.  Readmission, morbidity, and mortality are 
typical (negative) measures of unsuccessful transitions reported in the 
transitional care literature.  In fact, readmission rates following AMIs is one of the 
three conditions currently being monitored by the Hospital Quality Alliance as a 
measure of transitional success or failure (Jha, Orav, & Epstein, 2009).   
Relationships between concepts.  System and clinician concepts 
correspond to having the necessary resources and commitment to use resources 
in a prescribed manner consistent with standardized guidelines (i.e. AHA/ACC 
guidelines).  For example, the system must provide a means for communicating 
and sharing information with providers.  Clinicians must be able to utilize the 
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system efficiently and effectively.  Systems have policies and procedures that 
govern behavior of its employees and clinicians must work within these 
boundaries.  It is insufficient to have the tools if they are not utilized, or to have 
the desire to act, if it is not permitted.  The two are inextricably linked.  
 In the model depiction, the linkage between clinician and system is 
designated by the connecting dotted lines.  These linkages are propositional 
statements about the relationship between the system and clinician behavior.  
The specific system and clinician concepts represented in this model correspond 
to the objectives identified by the Agency for Healthcare Research and Quality 
discharge goals as contributors to rehospitalization and other early adverse 
events described in the literature (Arora & Farnan, 2008; Chiu & Newcomer, 
2007; Cumbler et al., 2008; Greenwald & Jack, 2009; Jacob & Poletick, 2008; 
Krumholz et al., 2002; Naylor et al., 2004; Phillips et al., 2004; Sinclair et al., 
2005; Stewart & Horowitz, 2002; Stewart et al., 1998).  It is also noted that the 
system may independently influence clinician behavior outside of the interactions 
with patients.   
 Both the institutional environment and the clinician have direct effects on 
the patient.  The combined interaction of the clinician, the system, and the client 
translates to outcomes.  If the system does not have all of the structural 
components, the actions of the clinician may counterbalance this, maintaining an 
even trajectory toward a positive outcome.  Conversely, if a clinician’s practice is 
below the expected standard, the system checks and balances may serve as a 
counterbalance.  Patient-specific variables may cause imbalances as well.  The 
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patient may have a number of risks, but may be very compliant with secondary 
lifestyle modification under the proper influences of the clinician with the support 
of the system.  The net effect results in the arrow remaining straight in its 
trajectory.  To come full circle and enable ongoing quality improvement efforts, it 
is essential that outcomes be translated back to the system and the clinician, as 
depicted by the dotted unidirectional arrows. 
BRIDGE Clinic Model of Care 
 The Integrated Client-Focused Transitional Care Model provides a 
framework for the overall hospital-to-home transition and is suitably broad to 
support a variety of transitional interventions.  Like this model, Bridging the 
Discharge Gap Effectively (BRIDGE) is an intervention that aims to positively 
influence client behavior while simultaneously providing a check and balance of 
both the system and its clinicians.  The nurse practitioner clinic is the cornerstone 
of the BRIDGE program.  The clinic utilizes the joint ACC/AHA ACS guidelines as 
the best-practice model for secondary prevention of an ACS event.  These 
guidelines emphasize discharge medications, lifestyle modifications, prompt 
follow up, and education about medication, therapeutics, lifestyle modification, 
signs and symptoms of danger, and when to call for help.  The goals of the 
BRIDGE model are consistent with these guidelines. 
BRIDGE Clinic Goals 
1. Provide seamless care to individuals discharged from UMHS with ACS 
2. Enhance compliance with evidence-based treatments 
3. Improve clinical outcomes 
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4. Decrease readmissions 
5. Decrease inappropriate use of acute care services (Housholder & Norville, 
2009, p. 1) 
 In order to meet these goals, nurse practitioners (NPs) assess the clinical 
status of the patient and his/her treatment response and then make therapeutic 
adjustments as needed.  The NPs also provide education about the client’s 
condition, medications, and what happened during their hospitalization.  Finally, 
they ensure that appropriate follow-up visits and referrals are in place 
(Housholder & Norville, 2009).  
 The underlying principles of the BRIDGE program are congruent with the 
Information-Motivation-Behavioral Skills Model (IMB), which stipulates that 
information, motivation, and behavioral skills are necessary determinants of 
health behavior.  In other words, when individuals are appropriately informed, 
sufficiently motivated to act, and have the skills to do so, they are more likely to 
initiate and maintain health-promoting behavior (Fisher, Amico, Fisher, & 
Harman, 2008; Fisher & Fisher, 2002; Fisher & Fisher, 2003).  This behavioral 
health model supports the investigation of hypothesis 1 (Patients seen in the 
BRIDGE clinic will have higher rates of persistence to secondary prevention 
medications at six-months than patients not followed in the BRIDGE clinic).  The 
NPs provide information about the benefits of β-blockers, ACE-inhibitors, aspirin, 
statins and clopidogrel in preventing secondary events and managing current 
symptoms.  The NPs discuss proper administration and access to these 
therapies.  As part of this education, the NPs directly influence clients’ individual 
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attitudes and belief about their ability to take these medications and the positive 
benefits of doing so.  When possible, the NPs include family members and 
support people in these discussions to enhance the social support and long-term 
encouragement toward adherence. 
 By helping patients develop the skills necessary to initiate and maintain 
adherence behaviors, it is expected that patients receiving this type of one-on-
one follow-up will be more compliant than those who do not.  While hypothesis 1 
reflects overall patient persistence with secondary prevention therapies 
prescribed at discharge, other possible health outcomes could be measured as 
well.  For example, because β-blockers lower heart rate, one possible measure 
would be to assess whether heart rates at 6-month post discharge are optimal.  
Similarly, lipid measurements reflect statin utilization.  While these are client-
specific health outcomes, the adherence to these specific measures is directly 
associated with lower morbidity and mortality and fewer rehospitalizations.   
 Application of the Integrated Client-Focused Transitional Care Model 
and BRIDGE.  The BRIDGE Transitional Care program, operating under the IMB 
philosophy and couched within the Integrated Client-Focused Transitional Care 
Model, is unique.  The overall BRIDGE concept begins at the system level.  
UMHS provides the type of teaching, learning, and evidence-based milieu 
essential for a successful transitional care program.  UMHS has state-of-the-art 
communications and informational technology services that connect its vast 
inpatient and outpatient network.  When patients are admitted with a diagnosis of 
ACS, for example, a critical pathway is immediately established and standardized 
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admission orders prompt providers to make use of the joint ACC/AHA ACS 
guidelines during the course of the patient’s stay.  Similar protocols are in place 
at discharge for β-blockers, ACE-inhibitors, aspirin, statins and clopidogrel, and 
justification is required when they are not prescribed.  A discharge prompt also 
alerts providers when patients do not have timely follow-up scheduled (within 2 
weeks).  Clinicians are able to utilize the enhanced informational technology and 
communication systems available to them at UMHS to rapidly transmit discharge 
information directly to cardiologists, primary care providers, and the BRIDGE 
clinic.  This is an essential step in linking inpatient to outpatient care. Discharge 
education is provided by both nurses and physicians to ensure that patients and 
families understand and have access to prescribed medications and protocols 
and recommended lifestyle modifications (including immediate referrals to 
smoking cessation programs). Patients must be made cognizant of the signs and 
symptoms of danger in order to be safely discharged and to avoid future 
complications.  Together these system and clinician measures provide clients 
with the necessary skills to successfully care for themselves after discharge.  
 Unfortunately, for a number of reasons, patients and families may not 
recall education imparted at discharge.  Although written information on all 
medications is provided and serves to minimize some confusion, it does not 
mitigate other issues.  For example, patients will sometimes receive prescriptions 
for medications in the same class as those they already have at home.  Patients 
may take both or not know which to take.  At times, prescriptions may have been 
forgotten at discharge, or patients may not have filled them.  For a variety of 
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reasons, patients may have discontinued their medications without informing 
anyone, or simply exhausted their supply before their next visit with another 
healthcare provider.  In light of the IMB Model, patients are thus lacking both the 
knowledge and skill to adhere to their prescribed program.  A successful 
transitional care model must address this issue and offer a means to correct it.  
BRIDGE does this in that the NPs assess the patient’s response to treatment and 
reinforce the education that clients and families need to best adhere to a 
therapeutic regimen (medication or lifestyle modification). Doing so helps "bridge" 
the chasm between the system and clinician and empowers clients toward better 
self care management. 
 Indeed, the truly unique aspect of BRIDGE is its collaboration with the rest 
of the health care system.  BRIDGE does not serve as an alternate cardiology 
follow-up or take patients away from outpatient providers.  Rather, the BRIDGE 
NPs practice independently, but when concerns arise, they first collaborate with 
the discharging physician or team.  The discharge team has the most recent 
experience with the patient and can direct interventions where necessary.  This is 
a novel organizational structure, as often the discharging team is not involved in 
any outpatient management.  When, for whatever reason, a member of the 
discharge team is not available, the NPs have collaborative practice agreements 
with onsite cardiologists who are always willing to intervene.  This feedback loop 
enables quality controls on both what occurs at discharge and what transpires 
after the patient goes home. 
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Preliminary Studies  
 When the BRIDGE clinic began operation in 2007, a clinical database was 
established to track the types of patients being seen and the effectiveness of the 
overall model.  An initial review of this data, for the period from July 2008 through 
February 2009 revealed interesting findings warranting further study.  As seen in 
Table 1, the average time from discharge to follow up with a cardiologist for all 
patients (N=342), whether participants in the BRIDGE program or not, was an 
astonishing 70.6 days whereas the average length from discharge to BRIDGE 
clinic was 19.5 days.  The 30-day readmission rate for patients seen in the 
BRIDGE clinic was 8.5%, far less than the percentage of readmissions for 
patients who chose not to attend (21.2%), and well below the estimated national 
rate of 19.9% (Krumholz et al., 2009). This data thus supported BRIDGE’s early 
success in preventing hospital readmission among BRIDGE users when 
compared to those who had more traditional follow-up. Why this occurred and 
what its effects were more broadly to the client and system remains to be 
examined in this study. 
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Table 1 
Preliminary Data from BRIDGE Registry 







Age (mean yr + SD) 64.1 + 15.0 61.0 + 14.8 0.075 
Male (%) 128 (55.4) 62 (55.7) 0.959 
Days to BRIDGE (mean yr + SD) 19.5 + 17.8 N/A N/A 
Days to Cardiologist (mean yr + SD) 75.0 + 54.9 53.0 + 55.5 0.006 
Days to any provider (mean yr + SD) 38.2 + 56.2 38.0 + 61.0 0.985 
30-day Readmission (%) 19 (8.5) 21 (21.2) 0.001 
Research Design and Methodologies in the Current Study  
Design 
 This study analyzes data from the observational BRIDGE Registry to 
investigate the outcomes and efficacy of the nurse practitioner-driven BRIDGE 
program as a model for delivering transitional care.  As noted earlier, the study’s 
three specific aims will be addressed in three separate but related papers 
(Chapters 2-4).  First, the 6-month post-discharge medication persistence rates 
(for β-blockers, ACE-inhibitors, aspirin, statins and clopidogrel) will be compared 
between patients who participated in the BRIDGE program and those who did 
not.  Second, the 30-day readmission rate for ACS patients will be compared 
between patients who participated in BRIDGE and those who did not.  Third, the 
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cost and effectiveness of the BRIDGE program will be compared to usual care 
and avoided rehospitalizations as a result of the program.  
The Human Subjects Internal Review Board (IRB) of the University of 
Michigan Medical Center approved this study (HUM00035421).  As there was no 
direct patient intervention in this study, and only minimal patient risk, therefore 
informed consent was waived.  Because of the study design and restrictions on 
the IRB waiver, no socioeconomic data were collected. 
Setting 
 The University of Michigan’s approach to managing the transitional care 
gap for CV patients and their high rates of early readmissions is novel.  Bridging 
the Discharge Gap Effectively (BRIDGE) is a program designed to ensure that 
patients who are discharged after an ACS event have support through the 
hospital-to-home transition. The ambulatory clinic is staffed by independent, 
specialized, cardiovascular nurse practitioners, who function in collaboration with 
on-site cardiologists and who act as an extension of the in-hospital care team 
(Housholder & Norville, 2009).  
 The five expert cardiology nurse practitioners delivering the BRIDGE 
program each have a minimum of 25 years of cardiovascular nursing experience. 
They are all certified by the American Nurses Credentialing Center as either 
acute care or adult nurse practitioners.  The NPs have monthly training, lectures, 
and seminars, provided by national experts in the field, to maintain currency and 
stay abreast of evidence-based changes to the care of ACS patients. 
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Sample 
 The BRIDGE registry contains data on all patients referred to the 
cardiovascular BRIDGE Clinic.  Patients are enrolled in the registry if they 
received a BRIDGE referral at the time of discharge (refer to the patient flow 
diagram, Figure 2).  Referrals are made to the BRIDGE program based on 
whether or not a patient has a follow-up appointment scheduled with their 
cardiologist or primary care provider within 14 days of discharge.  The 
discharging physician is prompted to make this referral if no follow-up is 
documented.  The Health System tracks all BRIDGE referrals.  Each scheduled 
appointment, regardless of patients’ participation, constitutes a unique entry into 
the BRIDGE registry. 
 Data from March 30, 2008 through March 30, 2009 were analyzed to 
address the differences between subjects who attended BRIDGE and those who 
did not.  Thus, patients discharged between March 30, 2008 and March 30, 2009 
were divided into two cohorts: an intervention group consisting of all patients who 
participated in the BRIDGE program during that period and a control group 
consisting of patients who were referred but did not participate in the program 
during the same period.  Determinations of six-month medication continuation 
rates were calculated through six-months after the discharge date. Patients 
were excluded from the medication continuation portion of the study if they 
lacked follow-up data at six-months, had contraindications to medications for 
secondary prevention of events, or died.  Patients were also excluded from the 
full study if they were pregnant, followed-up outside of the health system, or were 
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readmitted or died prior to their initial BRIDGE clinic appointment.  The Social 
Security Death Index was queried at the time of data abstraction for patients 
lacking follow up to determine if they died within the study period. 
 
Intervention 
 Client participation in the BRIDGE clinic was the intervention in this study.  
As noted earlier, five specially trained cardiology nurse practitioners (NPs) 
independently provide care in the BRIDGE clinic with medical collaboration and 
support as an extension of the discharge team.  In a one-time visit with each 
patient, the NP does a comprehensive review of the hospital course and 
Figure 2.  Patient flow diagram of the full BRIDGE Registry 
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discharge plan and performs a thorough history and physical exam.  The NP then 
evaluates the patient’s knowledge and understanding of his/her diagnosis and 
treatment while reviewing each ordered test and medication.  All NPs ensure that 
the American College of Cardiology/American Heart Association guidelines for 
secondary prevention medications have been prescribed and adjust medications 
and dosages depending on the patient’s responses and/or side effects.  The NPs 
also verify that all future tests and appointments have been scheduled and that 
proper referrals have been made.  The combination of a comprehensive history 
and physical appraisal with education, resources, and proper follow-up aim to 
minimize the gaps in care during the hospital-to-home transition. 
Instruments 
 Two major instruments were employed to gather data across all three 
papers. 
 Charlson Comorbidity Index (CCI).  The CCI is a tool designed to 
quantify the combined effects and severity of 19 comorbid conditions on 
mortality.  Each condition is weighted by its adjusted relative risk of mortality at 1 
year to accommodate for the significant prognostic differences among the 
conditions (Charlson, Pompei, Ales, & MacKenzie, 1987).  The chart tool is 
simple to use and requires only knowledge of the patient’s comorbid conditions 
and their assigned weights.  The sum (a continuous measure) of the individual 
weights classifies the level of comorbidity.  One year and ten year mortality rates 
can be calculated for four distinct CCI score groups; 0, 1-2, 3-4, > 5, with higher 
 40 
CCI scores associated with higher mortality (Charlson et al., 1987; Charlson, 
Szatrowski, Peterson, & Gold, 1994).   
 The CCI was developed in 1987 and modified to include age in 1994.  For 
the purpose of this study, the original measure was used, as age is an 
independent risk for CVD (Wilson et al., 1998).  Both tools have been tested in a 
variety of populations and settings and were consistently found to be valid tools 
for predicting mortality and adjusting risk (Needham, Scales, Laupacis, & 
Pronovost, 2005).  The CCI served as a proxy for an individual’s overall severity 
of illness. 
 GRACE risk score.  The GRACE risk score for discharge is a tool to 
predict the risk of death in patients with acute coronary syndrome from hospital 
discharge to six months out.  In this model, nine items were found to be 
multivariate predictors of mortality, with a c-statistic between 0.70 and 0.80, for 
all ACS patients (Eagle, Lim, et al., 2004).  The variables included were age, 
heart rate, systolic blood pressure, creatinine level, and the presence or history 
of congestive heart failure, in-hospital percutaneous intervention, in-hospital 
coronary artery bypass graft surgery, past history of an AMI, ST-segment 
depression, and/or elevated cardiac enzymes (Eagle, Lim, et al., 2004).  The tool 
assigns point values for levels of each variable.  The sum (a continuous 
measure) of the points is then cross-referenced with the probability of in-hospital 
death (Granger et al., 2003).  The discriminatory and predictive validity of this 
tool has been widely published (Elbarouni et al., 2009; Ramsay, Podogrodzka, 
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McClure, & Fox, 2007).  The GRACE score was used in this study to adjust for 
the severity of the patient’s ACS event.   
Data Collection 
 BRIDGE.  Consecutive data for all patients referred to the BRIDGE 
program were collected into a de-identified, online, clinical database.  Patients 
who did not show or who cancelled their appointments received a follow up 
phone call to determine the cause.  The BRIDGE registry is maintained by The 
Michigan Cardiovascular Outcomes Research and Reporting Program (M-
CORRP), a division of Cardiovascular Medicine specifically charged with 
developing and maintaining clinical registries for the purpose of advancing the 
science of cardiovascular medicine and improving the quality of care received by 
all patients in the UMHS system. 
 Recording of the registry population occurred in two phases.  First, data 
were collected by direct chart audit.  Second, data were manually entered into 
the online registry.  The data abstraction form (see Figure 3) shows the variables 
included in this registry.  Basic demographic, admission, discharge data, and 6-
month follow-up data were collected. Additionally, detailed information pertaining 
to medications and the components necessary to calculate the CCI score and the 
GRACE Risk Score were incorporated.  The tool has been refined since the 
preliminary clinical data collection in November of 2008 and has undergone 






 Data collection was done retrospectively by trained BRIDGE staff through 
M-CORRP.  The study team included research trainees, medical students, 
residents, and nursing students, who all worked under the direct supervision of 
M-CORRP faculty and the PI.  To ensure reliability and consistency in the 
Figure 3.  Data collection tool.  Reprinted with permission from M-CORRP 
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process, all data abstractors attended a 10 week series of seminars on 
cardiovascular disease and UMHS policies and procedures.  Further, all team 
members received training on variable definitions, how to abstract and record 
data on the BRIDGE case report form, and how to operate the Drupal interface 
for online data collection. This study design allowed 6-month follow-up data to be 
collected simultaneously.  
 The patient registration number was the only personal health identification 
variable collected.  To minimize patient risk, a subject identifier was generated 
when each patient was entered into the database.  As the registration number 
was inputted into the database, a two-way encryption method known as 
Mcrypt_AES_256 transformed the registration number into unusable information.  
The only retrieval mechanism was to input a decryption key.  Only the study 
investigators had authority to approve this procedure and the PI supervised its 
use throughout the process.  The Social Security Death Index was queried at the 
time of data abstraction for patients lost to follow-up.  No Social Security 
numbers were written down or kept electronically; only the result of the query (i.e. 
death) was recorded. 
 Four separate measures ensured the quality of data recorded within this 
registry.  First, the first five cases for all trainees were dually abstracted.  Second, 
a designated data entry person, who was not the data abstractor, entered data 
and confirmed the absence of omissions or nonsense responses (i.e. a date of 
readmission before a date of discharge). Third, a 10% sample of all cases was 
flagged for review and verification by the principal investigator (PI).  Lastly, 
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diagnostics were run on the dataset to identify duplicate or unrealistic entries (i.e 
length of stay greater that 1 year).  The PI and M-CORRP Research Manager 
resolved any discrepancies by reviewing original chart documentation.   
Data Analysis 
 In order to address the three specific aims, three different analyses were 
performed.  In chapter 2, a logistic regression analysis was used to explore how 
both patient and clinical factors explain medication persistence behavior.  In 
chapter 3, rates were calculated to determine differences in hospital readmission 
between BRIDGE participants and usual care.  Finally in chapter 4, a cost model 
was developed to compare costs associated with hospital readmission. 
Summary 
 Each of the three following papers explore a single component of the 
Integrated Client-Focused Transitional Care Model.  In chapter 2, the client-
specific characteristic of medication persistence is examined.  In chapter 3, 
readmission rates are measured as an outcome.  In chapter 4, the system 
influence of cost is investigated.  Though three separate and unique issues, as a 
result of the three-manuscript format of this dissertation, there is necessary 
redundancy within the background and significance and methods sections of the 
first four chapters.  The overarching theme of transitional care is revisited in each 
manuscript, and similarly, methodology is presented in each paper despite only 
the data analyses varying between papers.
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Appendix 
A Visual Representation of Coronary Disease Classifications 
 
 
Cardiovascular Disease (CVD) 
Coronary Heart Disease (CHD) 
Acute Coronary Syndrome (ACS) 
 Unstable Angina (USA) 
Acute Myocardial Infarction (AMI) 
 ST Elevated Myocardial Infarction (STEMI) 
 Non-ST Elevated Myocardial Infarction (NSTEMI) 
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CHAPTER II 
THE BRIDGE PROGRAM IMPROVES MEDICATION PERSISTENCE 
Introduction 
It is estimated that 785,000 Americans will suffer a first coronary event this 
year and that another 470,000 will experience some recurrent cardiac event 
(Roger et al., 2011).  These trends have given rise to the need for evidenced-
based guidelines that focus on secondary prevention across all aspects of acute 
coronary syndrome (ACS).  One of the leading efforts in secondary prevention is 
the American Heart Associations’ (AHA) Get with the Guidelines, which when 
adhered to by patients, providers and health systems, demonstrates significant 
reductions in both morbidity and mortality among ACS patients (Mehta et al., 
2004).  These guidelines encourage education on diet, exercise, weight 
management, smoking cessation, comorbid disease management, stress 
reduction, and strict and ongoing adherence to a medical regimen of β-
adrenergic blockers (β-blockers), angiotensin-converting enzyme inhibitors (ACE-
inhibitors; or angiotensin receptor blockers [ARBs] if ACE-inhibitor intolerant), 
aspirin, and statins, along with clopidogrel for up to one year following an event 
(Anderson et al., 2011; Antman et al., 2004; Antman et al., 2009).   β-blockers 
reduce cardiac workload and are potent anti-ischemic agents offering both 
cardio-protection and pain relief.   ACE-inhibitors or ARBs provide additional 
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protection against cardiac muscle damage and decrease ventricular dilation over 
time to decrease the incidence of future ACS events and comorbid 
consequences (Antman et al., 2004).  Antiplatelet agents reduce thrombus 
formation in atherosclerotic vessels.  There is overwhelming evidence that 
platelet inhibition via aspirin is highly effective at reducing ACS events 
(Antithrombotic Trialists' Collaboration, 2002). Statin therapy reduces atherogenic 
circulating lipids to prevent arteriosclerosis known to increase risk for both fatal 
and nonfatal AMIs (National Cholesterol Education Program, 2002). The 
synergistic effects of these four drug classes have been widely documented 
(Hippisley-Cox & Coupland, 2005; Mukherjee et al., 2004; Wald & Law, 2003) yet 
full compliance remains lower than desired (Choudhry, Avorn, Antman, 
Schneeweiss, & Shrank, 2007). Clopidogrel is the newest agent added to this 
secondary prevention regimen.  Initially recommended only in aspirin intolerant 
patients or in patients post percutaneous interventions for at least 2 weeks in 
combination with aspirin (Antman et al., 2004), clopidogrel is now recommended 
in all patients for a full year after an ACS event (Anderson et al., 2011; Smith Jr 
et al., 2006).  Antiplatelet therapy in general reduces mortality and morbidity due 
to vascular causes in patients with ACS (Antithrombotic Trialists' Collaboration, 
2002).  In the Clopidogrel in Unstable Angina to Prevent Recurrent Events 
(CURE) trial (Yusuf et al., 2001) and the Clopidogrel versus aspirin in Patients at 
Risk of Ischemic Events (CAPRIE) trial (CAPRIE Steering Committee, 1996) 
further reductions in adverse events were noted with the combination of aspirin 
and clopidogrel. 
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The consequences of discontinuing any one of these medications are well 
established. Patients who stop aspirin or beta-blocker therapy are at nearly twice 
the risk of death as patients who continue therapy. Patients who discontinue their 
statin are almost three times more likely to die than are persistent users.  
Patients who discontinue all three of these agents have a five-fold increased 
mortality over patients who continue on at least one or two agents (Ho et al., 
2006).  Aside from decreased mortality risk, patients who adhere to evidence-
based medication regimens have lower hospitalization rates; the costs incurred 
by their medications are then offset by reductions in healthcare utilization 
(Choudhry et al., 2008; Sokol et al., 2005).   
 Despite abundant evidence supporting the importance of medication for 
secondary prevention, numerous studies report poor rates of medication 
persistence among patients at high risk for secondary events.  Ackincigil et al. 
(2008) found that 18% and 22% of patients respectively discontinued their ß-
blockers and ACE-inhibitors at 6 months (Akincigil et al., 2008), while Benner et 
al. (2002) reported even lower continuation rates for statins (56%).  Examining 
ACS patients over one year, Newby, LaPointe, Nancy and Chen (2006) found 
that only 71% of patients remained on aspirin.  According to Ramsay et al. 
(2006), less than 20% of all AMI patients continue on their 4-drug regimen as 
recommended.  Those who remained on at least a 4-drug regimen reduced their 
risk of death by 87%.   
 There are many reasons why patients do not take their medications. 
Exorbitant medication costs, the patient’s lack of knowledge about his condition 
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and/or understanding of how the medication benefits his condition, medication 
side effects, and religious beliefs are just a few.  As patients’ lengths of hospital 
stay decrease, moreover, so do opportunities for inpatient education that may 
moderate these factors.  Even under ideal circumstances where patient 
education has been accomplished, for example, patients may not have the 
capacity to retain such knowledge after hospital discharge.  Education alone may 
not prepare patients for common errors such as duplicate medication classes 
(with medications they have at home), non-formulary substitutions, inadequate 
therapeutic responses, and untoward side effects that occur after discharge. 
Even when patients are motivated to seek early follow-up care, appointments 
with a cardiologist may not be available for months.  Many patients do seek 
follow-up with their primary care provider, only to be referred back to their 
hospital specialist.  Delays in follow-up visits are missed opportunities for 
medication reconciliation, assessment of the patient’s response to treatment, and 
reinforcement of discharge teaching that help prevent early adverse events that 
lead to ED visits, rehospitalization, and even death. 
Transitional care models utilizing nurse practitioners (NPs) may be the 
answer to the follow-up dilemma and its consequences.  NP models stress the 
importance of developing trusting relationships with patients and physicians, 
providing individualized education to patients and their supporters, offering 
known social services, simplifying drug regimens, and addressing side effects 
(Albert, 2008).   
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This is no truer than with NPs providing care in the Bridging the Discharge 
Gap Effectively (BRIDGE) program. Well versed in the ACC/AHA guidelines for 
secondary prevention of cardiac complications, they assess patients for 
medication side effects, drug interactions, duplications, omissions, and response, 
and make adjustments or changes to medication regimens when warranted.  In 
addition to medical management, the NPs provide essential education to patients 
and their families about their condition, how each medication works to help 
prevent future events, and the proper administration of each prescribed 
medication.  The NPs communicate as part of an interdisciplinary team to both 
the hospital and outpatient care support teams, and when necessary, work with 
community resources should patients have trouble paying for their prescriptions. 
Although these activities are aimed toward increasing patient persistence on care 
regimens, there has been no evidence to date that supports whether patients 
seen in BRIDGE are more likely to stay on their prescribed regimens over 
individuals who follow a more traditional follow-up pathway after hospital 
discharge. 
 To explicate whether patients seen in the BRIDGE program are more likely 
to adhere to their prescribed regimen for secondary prevention, this study 
compared the six-month medication persistence rates with β-blockers, ACE-
inhibitors (or ARBs), aspirin, statins, and clopidogrel following discharge from the 
hospital after an ACS event between patients who participated in the BRIDGE 
program and those who had usual care. Given the breadth of literature 
suggesting that transitional care models with NPs fill a critical gap in care delivery 
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to effect outcomes, the hypothesis was that compared with patients who received 
usual care, patients who participated in the BRIDGE program would have higher 




 This retrospective quasi-experimental study aimed to investigate the 
efficacy and outcomes of the NP-driven, BRIDGE program as a model for 
transitional care by comparing the 6-month post-discharge medication 
continuation rates (for β-blockers, ACE-inhibitors, aspirin, statins and clopidogrel) 
between patients who participated in the BRIDGE program and those who did 
not.     
Setting 
 The University of Michigan’s Bridging the Discharge Gap Effectively 
(BRIDGE) is a program designed to ensure that patients who are discharged 
after a cardiovascular (CV) event have support throughout the hospital-to-home 
transition. The clinic is staffed by five independent, specialized, cardiovascular 
nurse practitioners, who function in collaboration as an extension of the in-
hospital care team and, when needed, with onsite cardiologists. 
 Each of the NPs delivering the BRIDGE program has a minimum of 25 
years of cardiovascular nursing experience. They are all nationally certified by 
the American Nurses Credentialing Center as either acute care or adult nurse 
practitioners.  As such, they have had, and continue to have, monthly training, 
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lectures, and seminars provided by national experts in the field in order to 
maintain their clinical competence and currency, particularly as it pertains to and 
the care of CV patients. 
Sample 
 All patients over 18 years of age discharged from the University of 
Michigan Health System (UMHS) between March 30, 2008 and March 30, 2009 
who were admitted either for a CV event or required a cardiology consultation 
during their stay were eligible for this study.  Patients were enrolled in the study if 
they received a BRIDGE referral at the time of discharge.  Referrals were made 
to the BRIDGE program based on whether or not a patient had a follow-up 
appointment scheduled with their cardiologist or primary care provider within 14 
days of discharge.  The discharging physician was prompted to make this referral 
if no follow-up appointments existed.  The Health System tracked all BRIDGE 
referrals.  Each scheduled appointment, regardless of patients’ participation, 
constituted a unique entry into the BRIDGE registry. 
Patients discharged were then divided into two cohorts: an intervention 
group consisting of all patients who participated in the BRIDGE program during 
that period, and a control group consisting of patients who were referred to but 
did not participate in the program during the same period.  Determination of six-
month medication continuation rates between the 2 groups was analyzed through 
six-months after the discharge date.  Patients were excluded from the medication 
continuation portion of the study if they lacked follow-up data at six-months, had 
contraindications to medications for secondary prevention of events, or expired.  
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Patients were also excluded from the full study if they became pregnant, sought 
follow-up outside of the University of Michigan health system, or expired within 
30 days of discharge.  The Social Security Death Index was queried for patients 
lost to follow-up. 
 The study cohort included 424 patients referred to the general medicine 
cardiology BRIDGE program between March 30, 2008 and March 30, 2009.  All 
patients who met the inclusion criteria and did not have follow-up scheduled 
within 14 days of discharge were referred.  The subset of patients with ACS 
comprised 25.7% (n=109) of these referrals. Patients were excluded if they died 
or were rehospitalized prior to their initial BRIDGE appointment (n=11, 10.3%), 
The final study sample included 97 patients after excluding patients with missing 
variables (n=1, 1.0%).  See the patient flow (see Figure 4). 
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Figure 4.  Patient flow diagram for analysis of medication persistence. 
Measures 
 Two principal measures were used to extrapolate and analyze data to 
answer the study specific aims. 
 Charlson Comorbidity Index (CCI).  The CCI is a tool designed to 
quantify the combined effects and severity of 19 comorbid conditions on 
mortality.  Each condition is weighted by its adjusted relative risk of mortality at 1 
year to accommodate for the significant prognostic differences among the 
conditions (Charlson et al., 1987).  The chart tool is simple to use and requires 
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only knowledge of the patient’s comorbid conditions and the assigned weights.  
The sum (a continuous measure) of the individual weights classifies the level of 
comorbidity.  One year and ten year mortality rates can be calculated.  The range 
of possible scores depends on the number and severity of comorbid conditions 
within the study population.  Higher CCI scores are associated with higher 
mortality (Charlson et al., 1987; Charlson et al., 1994).   
 Developed in 1987, the CCI has been tested across a variety of 
populations and settings and has consistently proven valid for predicting mortality 
and for risk adjusting (Needham et al., 2005).  Given that greater numbers of 
comorbid conditions and the severity of those conditions is associated with 
poorer long-term outcomes, the CCI served as a proxy for overall severity of 
illness in this study. 
 GRACE Risk Score.  The GRACE Risk Model for discharge was used to 
predict the risk of death in patients with acute coronary syndrome from discharge 
to six months after hospital discharge.  The tool is simple and can be used in 
general clinical practice.  Nine items were found to be multivariate predictors of 
mortality, with a c-statistic between 0.70 and 0.80 for all ACS patients (Eagle, 
Lim, et al., 2004).  The nine variables were age, heart rate, systolic blood 
pressure, creatinine level, the presence or history of congestive heart failure, in-
hospital percutaneous intervention, in-hospital coronary artery bypass graft 
surgery, past history of an AMI, ST-segment depression, and elevated cardiac 
enzymes (Eagle, Lim, et al., 2004).  The tool assigned point values for levels of 
each variable such that individuals with higher risks had greater point value 
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(possible range 70 to 210).  The sum (a continuous measure) of the points was 
then cross referenced with the probability of in-hospital death (Granger et al., 
2003).  The discriminatory and predictive validity of this tool has been widely 
published (Elbarouni et al., 2009; Ramsay et al., 2007).  
Approach 
BRIDGE.  The Michigan Cardiovascular Outcomes Research and 
Reporting Program (M-CORRP) maintains the BRIDGE registry.  M-CORRP is a 
division of cardiovascular medicine specifically charged with developing and 
maintaining clinical registries for the purpose of advancing the science of 
cardiovascular medicine and improving the quality of care received by all 
patients.  Data collection was performed retrospectively.  Designated study 
research trainees (medical and research students working under the direction of 
M-CORRP and the PI) abstracted and entered data.   
Three separate measures were in place to ensure the quality of data 
recorded within the registry.  The first five cases for all trainees were separately 
abstracted and entered in the database and compared to the original case entry.  
Random 10% samples of all cases were flagged for repeat abstraction and data 
re-entry verification.  The PI and M-CORRP Research Manager resolved any 
discrepancies.  
Consecutive data for all patients referred to the BRIDGE program were 
collected into a de-identified, online, clinical database using a data abstraction 
form specific to this registry (see Figure 3, chapter 1).  Data collected on each 
participant included basic demographics, admission data, discharge data, and 6-
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month follow-up data, as well as detailed information pertaining to medications 
and the components necessary to calculate the CCI and GRACE Risk Scores.  
The latter items, as noted earlier, were critical in order to adjust for an individual’s 
overall severity of illness (CCI) and the severity of the patient’s ACS event 
(Grace Risk Score).  Prior to its use, the data abstraction tool underwent 
extensive piloting and face validity testing.  Patients who did not present for their 
appointment or who cancelled their appointments received a follow-up phone call 
to determine the cause.  This data was also coded and contained in the 
database.   
Data Analysis 
 Outcome.  The main outcome for this analysis was medication persistence 
at six-months among ACS patients discharged on any combination of β-blockers, 
ACE-inhibitors (or ARBs), aspirin, statins, and clopidogrel. Persistence was 
defined as self-reported continued use of the medication six-months after 
discharge.  Six-month persistence rates were determined by comparing self-
reported medication regimens from the most complete cardiology or primary care 
follow-up notes six-months after discharge (no more than two weeks before and 
no more than one month beyond the six month discharge date) to the medication 
regimen prescribed at discharge.  The methodology described here to calculate 
persistence with evidence-based medication therapies after discharge is 
consistent with the methodology employed to determine medication adherence 
from the GRACE Registry (Eagle, Kline-Rogers, et al., 2004).  
Statistical Analysis.  Six-month medication persistence rates for β-
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blockers, ACE-inhibitors (or ARBs), aspirin, statins, clopidogrel, and the 
combination of 3, 4, and 5 drug regimens were compared between BRIDGE 
attendees and non-attendees using the chi square test. Pearson’s chi-square test 
for significance is reported except in cases where the expected count would 
violate an underlying assumption; in these cases, Fisher’s Exact test is reported.  
Patients with known contraindications or hypersensitivity reactions to certain 
medications, such that they could not be prescribed or continue medication 
usage, were excluded.  Data were analyzed using PASW 18.0.  Baseline 
equivalencies were assessed for all demographic variables, comorbidities, and 
CCI and GRACE Risk scores.  All variables were assessed for compliance with 
statistical assumptions including normal distribution.  Missing data were excluded 
from the sample. 
Hierarchical logistic regression models were used for each class of 
medication to evaluate the first hypothesis that BRIDGE attendance would 
influence medication persistence after adjusting for comorbidities (CCI) and 
severity of events (GRACE).  A significance level was set at 0.05 for all analyses. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were reported for all 
independent variables.    
Results 
Sample 
 Of 107 individuals discharged from UMHS after an ACS event, 97 were 
included in this analysis (refer back to Figure 4).  Although patients with early 
adverse events (EAE) resulting in death or readmission before their scheduled 
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BRIDGE appointment were excluded from the analysis, in view of the fact that 
they neither received the intervention nor had the opportunity to attend if they 
had chosen to do so, those who were excluded were compared to those who 
were included to ensure that there was no significant variation between groups.   
There were no significant baseline differences between groups in either 
demographics or the types of comorbid conditions present (see Table 2).  There 
were however, significant differences in both CCI and GRACE Risk scores.  
Patients who experienced an EAE had higher CCI and GRACE Risk scores, 
suggesting that these patients had more comorbid conditions or a more serious 
event, or both.   
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Table 2 





All Others  
n=98 (91.6%) p-value 
Age (mean +SD) 66.09 (14.96) 62.4 (13.9) .409 
Gender (% Female) 4 (44.4) 59 (60.2) .483 
Race    
White 7 (77.8) 83 (85.6) .622 
Non-white (Black, Asian,  
Native American, Hispanic)  
2 (22.2) 15 (14.4) .622 
Comorbidities    
Afib 1 (11.1) 7 (7.1) .517 
CVD 0 6 (6.1) 1.00 
Hx TIA 0 2 (2.0) 1.00 
Hx CVA 0 2 (2.0) 1.00 
CHF 2 (22.2) 12 (12.2) .334 
CAD  9 (100) 91 (92.9) 1.00 
Current Smoker 2 (22.2) 24 (24.5) 1.00 
Diabetes 3 (33.3) 30 (30.6) 1.00 
Dyslipidemia 5 (55.6) 71 (72.4) .279 
HTN 7 (77.8) 63 (64.3) .493 
Obesity 1 (11.1) 18 (18.4) 1.00 
Peripheral Vascular  1 (11.1) 12 (12.2) 1.00 
Psychiatric Disorder n=35 (32.7%) n=4 (44.4%) n=31 (31.6%)  
Anxiety 1 (25.0) 16 (51.6) .603 
Dementia 1 (25.0) 5 (16.1) .546 
Depression 3 (75.0) 24 (77.4) 1.00 
Substance 0 8 (25.8) .553 
Charlson Comorbidity  5.43+-2.30 3.98 +-1.79 .015 
GRACE Risk Score 123.00+-37.53 99.69+-30.79 .022 
aEarly adverse events (hospital readmission or death before BRIDGE appointment). 
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 The mean age of all study participants was 62.4 years.  The majority 
(59.8%) were female, and white (85.6%) with a median length of initial hospital 
stay ranging from 2-4 days.  Table 3 shows a comparison of patients who 
attended BRIDGE versus those who did not.  With the exception of a higher 
percentage of dyslipidemia among BRIDGE users and slightly elevated rates of 
depression among non-attenders, there were no significant differences between 
the two groups. 
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Table 3 




Did Not Attend 
n=27, (72.2%) p-value 
Age (mean +SD) 62.3+13.5 62.6+14.8 0.928 
Gender (% Female) 42 (60.0) 16 (59.3) 0.947 
Race    
White 59 (84.3) 24 (88.9) 0.751 
Non-white (Black, Asian,  
Native American, Hispanic)  
11 (15.7) 3 (11.1) 0.751 
Comorbidities    
Afib 6 (8.6) 1 (3.7) 0.669 
CVD 4 (5.7) 2 (7.4) 0.669 
Hx TIA 2 (2.9) 0 1.00 
Hx CVA 1 (1.4) 1 (3.7) 0.481 
CHF 8 (11.4) 4 (14.8) 0.733 
CAD 65 (92.9) 26 (96.3) .670 
Current Smoker 19 (27.1) 5 (18.5) 0.378 
Diabetes 23 (32.9) 7 (25.9) 0.508 
Dyslipidemia 57 (81.4) 14 (51.9) 0.003 
HTN 47 (67.1) 16 (59.3) 0.466 
Obesity 15 (21.4) 3 (11.1) 0.241 
Peripheral Vascular  7 (10.0) 5 (18.5) 0.305 
Psychiatric Disorder n=31(31.9%) n=17 (24.5%) n=14 (51.9%)  
Anxiety 9 (52.9) 7 (50.0) 0.870 
Dementia 3 (17.6) 2 (14.3) 1.000 
Depression 12 (70.6) 12 (85.7) 0.412 
Substance 4 (23.5) 4 (28.6) 1.000 
Charlson Comorbidity  3.98+1.75 4.11 +1.96 0.765 
GRACE Risk Score 99.63+30.8 103.44+30.8 0.585 
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Attendance 
 Overall, 77% (n=60) of referred patients attended their scheduled BRIDGE 
appointment.  The median time from discharge to follow-up in the BRIDGE clinic 
was 15 days.  There were differences between usual care (UC) and BRIDGE 
participants in median number of days from discharge to follow-up with any 
provider (UC median=15 days, BRIDGE median=20 days, p=.587) and with 
cardiology (UC median=31 days, BRIDGE median=59 days, p=.006).  The most 
common reason for not attending BRIDGE was obtaining an earlier appointment 
with one’s cardiologist or primary care provider (n=20/58 contacted by phone, 
34.5%).   
Medication Persistence 
 Overall rates of medication prescribing for secondary prevention in the 
population of study exceeded the rates in the literature for aspirin, β-blockers, 
and statins (Margulis, Choudhry, Dormuth, & Schneeweiss, 2011; Simpson, 
Beck, Richard, Eisenberg, & Pilote, 2003). Therefore, to show statistical 
significance over usual care in this institution is to show an improvement over 
care that is already above average.  The following results (see Table 4) describe 
patterns of attendance by medications prescribed at discharge and patterns of 




Rates of Medication Persistence by BRIDGE Attendance No.  (%) 








value OR 95% CI 
Prescribed at discharge       
Aspirin 97 95 (97.9) 69 (98.6) 26 (96.3) .481 2.654 [.160,44.004] 
β-blockers  97 86 (88.7) 62 (88.6) 24 (88.9) 1.00 .969 [.237,3.960] 
ACE-inhibitor/ARB 97 73 (75.3) 57 (81.4) 16 (59.8) .023 3.014 [1.136,7.998] 
Statin 97 92 (94.8) 68 (97.1) 24 (88.9) .130 4.250 [.669,26.995] 
Clopidogrel 97 72(75.5) 53 (75.7) 19 (73.1) .791 1.149 [.412,3.199] 
4 Drug 
Combinationa 
97 59 (60.8) 47 (67.1) 12 (44.4) .040 2.554 [1.030,6.335] 
5 Drug 
Combinationb 
97 46 (47.4) 36 (51.4) 10 (37.0) .203 1.800 [.724,4.476] 
Persistence at 6 months        
Aspirin 44 42 (95.5) 33 (97.1) 9 (90.0) .407 3.667 [.208,65.548] 
β-blockers  40 36 (90.0) 29 (93.5) 7 (77.8) .213 4.143 [.494,34.746] 
ACE-inhibitor/ARB 31 25 (80.6) 20 (80.0) 5 (83.3) 1.00 .800 [.076,8.474] 
Statin 44 40 (90.9) 31 (91.2) 9 (90.0) 1.00 1.148 [.106,12.427] 
Clopidogrel 35 30 (85.7) 22 (81.5) 8 (100.0) .315 -- -- 
Of patients Prescribed 4 agents      
Still on 0 agents 27 -- -- -- -- -- -- 
Still on 1-2 agents 32 8 (25.0) 1 (16.7) 7 (26.9) 1.00 1.842 [.182,18.65] 
Still on 3-4 agents 27 24 (88.9) 19 (86.4) 5 (100.0) 1.00 -- -- 
Of patients Prescribed 5 agents      
Still on 0 agents 21 -- -- -- -- -- -- 
Still on 1-2 agents 23 4 (17.4) 3 (16.7) 1 (20.0) 1.00 .800 [.065,9.919] 
Still on 3-4 agents 34 20 (58.8) 14 (53.8) 6 (75.0) .422 .389 [.112,2.024] 
Still on 5 agents 21 12 (57.1) 10 (58.8) 2 (50.0) 1.00 1.429 [.161,12.701] 
aAspirin, β-blockers, ACE-inhibitor/ARB, statin.  bFour agents plus clopidogrel. 
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 As can be seen, nearly all patients discharged with ACS were prescribed 
aspirin (97.9%).  Again, small numbers prohibit finding significance, but the trend 
here is also more difficult to interpret.  Most subjects remained on aspirin (95.5%) 
six months after discharge.  There were no differences between BRIDGE 
participants or participants receiving usual care and aspirin persistence 6 months 
after discharge. 
 Of those patients discharged with ACS, 88.7% were prescribed β-
blockers.  Being prescribed β-blockers had no impact on BRIDGE attendance 
(p=1.000*) and six months after discharge, 90% of the patients remained on β-
blocker therapy regardless of BRIDGE participation (p=.123*). 
 Only 75.3% of all patients were discharged on ACE-inhibitors (or ARBs if 
ACE-inhibitor intolerant). A higher percentage of patients treated with ACE-
inhibitors attended their scheduled BRIDGE appointment (p=.023) and six 
months after discharge ACE-inhibitor persistence increased for patients receiving 
usual care but remained 80.6% for all patients. 
 A high percentage of patients received prescriptions for statins at 
discharge (94.8%).  Statin therapy did not influence BRIDGE participation 
(p=.130).  Six-months after discharge a similarly high percentage of patients 
remained on their statins (90.9%) regardless of BRIDGE participation.   
 Of patients meeting the criteria for clopidogrel, 75.0% received a 
prescription at discharge.  Being prescribed clopidogrel did not impact BRIDGE 
attendance (p=. 791).  Six-months after discharge, 85.7% of patients remained 
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on their clopidogrel and there were no differences between those who attended 
or those who received usual care.   
 Logistic regression was used to predict the likelihood of medication 
persistence six-months after hospital discharge.  The analysis was limited by the 
number of patients for which there was medication persistence data available.  
Because of the small sample size, it was necessary to test a series of models 
rather than a single model.  Also, because the CCI and GRACE Risk Scores had 
significant multicollinearilty (r=.81, p< .000) they could not be combined in any 
models.  Three series of analyses were performed.  Each series tested the 
likelihood of medication persistence to aspirin, ß-blockers, ACE-inhibitors, 
statins, and clopidogrel individually and to the four and five drug combined 
pharmacotherapy regimens of aspirin, ß-blockers, ACE-inhibitors, statins (4 drug 
regimen) plus clopidogrel (5 drug regimen).  The first series of models tested only 
BRIDGE attendance.  The second series tested attendance after adjustment for 
CCI, by entering it in first.  Similarly, the third series tested attendance after 
adjustment for the GRACE Risk Score.   As shown in Table 5, only 4 of the 21 
models were predictive of medication persistence at six-months:  ß-blockers or 
ACE-inhibitors adjusted for either the CCI or GRACE Risk Score.  For ß-
blockers, the addition of the CCI to attendance explained between 22.9% (Cox 
and Snell R squared) and 47.8% (Nagelkerke R squared) of the variance in 
persistence six-months after hospital discharge.  Likewise testing attendance 
with the GRACE Risk Score explained between 25.4% (Cox and Snell R 
squared) and 53.1% (Nagelkerke R squared) of the variance in six-months 
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persistence.  The ACE-inhibitor model adjusted for the CCI explained between 
25.0% (Cox and Snell R squared) and 39.0% (Nagelkerke R squared) of the 
variance in persistence; and in combination with the GRACE Risk Score 
explained between 31.7% (Cox and Snell R squared) and 49.5% (Nagelkerke R 
squared) of the variance.  Further, the only independent variables to demonstrate 




Logistic Regression Models Predicting Likelihood of Medication Persistence Six- 
Months after Hospital Discharge by BRIDGE Attendance 
Unadjusted Models 
Medication ß Odds Ratio 95% CI 
Aspirin    
Constant 2.197 9.000  
Attend 1.269 3.556 .202, 62.63 
-2 Log Likelihood 15.464   
Chi-Square (df) .714 (1)   
% Correct classification 95.3   
    
Beta Blockers    
Constant 1.253 3.500  
Attend 1.421 4.143 .494, 34.746 
-2 Log Likelihood 24.366   
Chi-Square (df) 1.640 (1)   
Correct classification 90.0   
    
ACE-I/ARBs    
Constant 1.609 5.000  
Attend -.329 .720 .068, 7.661 
-2 Log Likelihood 29.492   
Chi-Square (df) .078 (1)   
Correct classification 79.3   
    
Statins    
Constant 2.197* 9.000  
Attend .105 1.111 .103, 12.037 
-2 Log Likelihood 26.608   
Chi-Square (df) .007 (1)   
Correct classification 90.7   
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Unadjusted Models Continued 
Medications ß Odds Ratio 95% CI 
Clopidogrel    
Constant 21.203 -  
Attend -19.768 -  
-2 Log Likelihood 25.457   
Chi-Square (df) 2.938 (1)   
Correct classification 85.3   
    
4 Agents    
Constant .405 1.500  
Attend .773 2.167 .262, 17.892 
-2 Log Likelihood 25.280   
Chi-Square (df) .502 (1)   
Correct classification 72.7   
    
5 Agents    
Constant .000 1.000  
Attend .916 2.500 .256, 24.375 
-2 Log Likelihood 22.297   
Chi-Square (df) .618 (1)   
Correct classification 66.7   
 Models Adjusted for Charlson Comorbidity Index 
Aspirin    
Constant 1.303 3.681  
Charlson .249 1.282 .053, .254 
Attend 1.253 3.500 .196, 62.65 
-2 Log Likelihood 15.159   
Chi-Square (df) 1.018 (2)   
% Correct classification 95.3   
    
Beta Blockers    
Constant -3.720 .024  
Charlson 1.702* 5.482 1.189, 25.272 
Attend 1.447 4.250 .285, 63.385 
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Models Adjusted for Charlson Comorbidity Index 
Medications ß Odds Ratio 95% CI 
-2 Log Likelihood 15.619   
Chi-Square (df) 10.388 (2)**   
Correct classification 92.5   
    
ACE-I/ARBs    
Constant 5.913* 369.69  
Charlson -.927* .396 .185, .848 
Attend -.280 .756 .036, 15.844 
-2 Log Likelihood 21.241   
Chi-Square (df) 8.329 (2)*   
Correct classification 86.2   
    
Statins    
Constant .887 2.428  
Charlson .409 1.505 .696, 3.257 
Attend -.088 .916 .078, 10.746 
-2 Log Likelihood 25.324   
Chi-Square (df) 1.291 (2)   
Correct classification 90.7   
    
Clopidogrel    
Constant - -  
Charlson - - - 
Attend - - - 
-2 Log Likelihood -   
Chi-Square (df) -   
Correct classification -   
    
4 Agents    
Constant 3.302 27.168  
Charlson -.728 .483 .204, 1.141 
Attend 
.843 2.324 .199, 27.183 
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Models Adjusted for Charlson Comorbidity Index 
Medications ß Odds Ratio 95% CI 
-2 Log Likelihood 21.572   
Chi-Square (df) 4.210 (2)   
Correct classification 81.8   
    
5 Agents    
Constant 2.7000 14.881  
Charlson -.692 .501 .207, 1.212 
Attend 1.013 2.754 .189, 40.146 
-2 Log Likelihood 19.056   
Chi-Square (df) 3.859 (2)   
Correct classification 72.2   
    
 Models Adjusted for GRACE Risk Score 
Aspirin    
Constant 2.452 11.610  
GRACE -.003 .997 .949-1.049 
Attend 1.281 3.600 .202, 64.03 
-2 Log Likelihood 15.454   
Chi-Square (df) .724 (2)   
% Correct classification 95.3   
    
Beta Blockers    
Constant -9.395 -  
GRACE .138* 1.147 1.006, 1.309 
Attend .904 2.469 .151, 40.485 
-2 Log Likelihood 14.298   
Chi-Square (df) 11.708** (2)   
Correct classification 95.0   
    
ACE-I/ARBs    
Constant 9.979* -  
GRACE -.077** .929 .874, .981 
Attend 
-.357 .700 .014, 33.970 
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Models Adjusted for Charlson Comorbidity Index 
Medications ß Odds Ratio 95% CI 
-2 Log Likelihood 18.529   
Chi-Square (df) 11.040 (2)**   
Correct classification 89.7   
    
Statins    
Constant .759 2.135  
GRACE .016 1.016 .971, 1.064 
Attend -.045 .956 .082, 11.103 
-2 Log Likelihood 26.065   
Chi-Square (df) .550 (2)   
Correct classification 90.7   
    
Clopidogrel    
Constant - -  
GRACE - - - 
Attend - - - 
-2 Log Likelihood -   
Chi-Square (df) -   
Correct classification -   
    
 Models Adjusted for GRACE Risk Score 
4 Agents    
Constant 5.450 232.733  
GRACE -.056 .946 .888, 1.007 
Attend 1.576 4.838 .260, 89.891 
-2 Log Likelihood 20.610   
Chi-Square (df) 5.172 (2)   
Correct classification 86.4   
    
5 Agents    
Constant 5.054 156.651  
GRACE -.055 .947 .877, 1.021 
Attend 
1.293 3.644 .191, 69.442 
 74 
Models Adjusted for Charlson Comorbidity Index 
Medications ß Odds Ratio 95% CI 
-2 Log Likelihood 18.964   
Chi-Square (df) 3.951 (2)   
Correct classification 77.8   
*p < .05, ** p < .01 
 
 In summary, there were no significant differences in six-month medication 
persistence for any individual medication (aspirin, β-blocker, ACE-inhibitor, statin, 
clopidogrel).  There were however, higher percentages of patients remaining on 
these therapies at 6-months after discharge who attended the BRIDGE program.  
Despite this finding, the small sample size and high rates of overall compliance 
may prevent observable significance.  There were also no differences in rates of 
adherence to 4 or 5-drug combinations.  Again, small numbers prohibit finding 
significance, but the trend here is also more difficult to interpret.  The trend 
suggests greater persistence for non-attendees in all categories except for those 
prescribed the full 5-drug regimen, where patients who attended BRIDGE 
demonstrate greater persistence.  However, with the exception of the β-blocker 
and ACE-inhibitor models combined with either the CCI or the GRACE Risk 
score, no models were predictive of medication persistence six-months after 
discharge.  Of note, all patients, whether BRIDGE attendees or non-attendees, 
remained on at least one medication to the six month period of evaluation. 
Discussion 
 This study measured differences in 6-month medication persistence rates 
of five secondary prevention agents between patients who received usual care 
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and those who attended the NP-driven, transitional care BRIDGE program.  
Patients discharged on aspirin, β-blockers, statins, or clopidogrel had no impact 
on their follow-up BRIDGE appointment.  However, more patients discharged on 
ACE-Is attended their BRIDGE appointment.  This result is unclear given that 
there were no apparent demographic differences or disease severity differences 
between the 2 groups.  One possible explanation may be that these patients 
received a stronger message from the discharge team regarding the need for 
early follow-up.  Further analyses will be necessary to determine if this finding is 
clinically relevant.   
 There were no differences in 6-month persistence rates between usual 
care and BRIDGE participants on any single drug class.  In fact, 6-month 
persistence for any single agent was high for all study participants; ranging from 
80.65% for ACE-Is to 95.5% for aspirin.  There was also no difference in 
persistence for ACE or statin use between BRIDGE participants and usual care.  
Higher proportions of patients who attended BRIDGE remained on aspirin and β-
blockers, but lower proportions stayed on clopidogrel.  It is unknown whether this 
reflects patient self-discontinuation or provider discontinuation.  Significantly 
more patients prescribed either the 4 or 5 drug regimens attended their BRIDGE 
appointments.  One possible explanation for this is that patients discharged on 
more medications may be more motivated to see a health care provider sooner 
due to side effects, questions, or confusion about their therapeutic regimen.   
 Given the small sample size, little can be concluded about the persistence 
habits of patients prescribed 4 or 5-drug regimens of combined 
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pharmacotherapy.  A larger sample is needed to more fully explore this question.  
However, despite there being no significant differences in persistence rates for 
patients prescribed combined pharmacotherapy, a higher percentage of patients 
who attended BRIDGE did remain on a 5-drug regimen six months after 
discharge and more patients under usual care reported continuing only 1-2 drugs 
of a 4 or 5-drug regimen.  Notably, there were no cases where patients were 
taking zero medications.  With the exception of the β-blocker and ACE-inhibitor 
models combined with either the CCI or the GRACE Risk score, no logistic 
regression models were predictive of medication persistence six-months after 
discharge.  Further research and a larger sample is needed to not only determine 
if the intervention group has higher persistence, but also to determine if lower 
persistence is the result of patient or provider discontinuation.  It is possible that 
the NPs of the BRIDGE clinic, or providers from subsequent visits over the six-
month follow-up period, may have discontinued medications.   
Limitations 
 This study adds to the growing body of literature on NP-delivered 
transitional care models.  It also provides further understanding of how patients 
take their prescribed medications.  It is also the first study to compare medication 
persistence after receiving usual care to participation in a transitional care 
program.  However, there are limitations that should be considered.  First, this 
study was conducted using an observational registry without randomization.  
Thus, this reduces the generalizability of the results as patients made their own 
decision whether or not to participate and therefore the groups were not likely to 
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be equivalent.  Still it has been argued that results from well done observational 
studies may more closely approximate usual care (Avorn, 2007).  This study 
does compare a therapeutic intervention to usual care as a measure of success 
and thus its findings can be viewed as more rigorous.  A second limitation 
pertains to the fact that the study institution has a high rate of compliance with 
evidence-based therapies, as is evidenced by the high discharge prescribing 
rates for cardio protective agents.  Comparison of medication prescription rates 
at the UMHS with those reported in the GRACE Registry revealed that β-blocker 
prescribing rates at discharge were 2.1% higher at UMHS than those reported in 
the GRACE registry, aspirin prescribing rates were 7.0% higher at UMHS and 
statins 14.4% higher at U of M. (Eagle, Kline-Rogers, et al., 2004).  Six-month 
continuation rates for both usual care and BRIDGE were 0.6% to 3.9% higher as 
well.  The success of the BRIDGE transitional care program should be viewed 
not only as providing benefit beyond usual care, but also as providing benefit 
beyond usual care in a setting where usual care is highly consistent with national 
guidelines. 
 Because data were collected retrospectively, causality should not be 
assumed.  Missing data or confounding variables may exist that were not taken 
into consideration.  To calculate drug persistence for example, patients who had 
contraindications to medications were excluded from the analysis.  Patients may 
have been misclassified if they had a troublesome effect or a contraindication to 
a drug prior to the index hospitalization that was not explicitly documented during 
this hospitalization.  This error may have resulted in an overestimation of 
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BRIDGE’s potential to improve medication persistence in participants (Mukherjee 
et al., 2004). 
 The sample size for this study, after exclusions and loss to follow-up, was 
also relatively small.  Due to the small sample size, differences between groups 
were small and statistical analyses were limited as were the development of 
more comprehensive logistic models.  A larger cohort is necessary to more fully 
explore these findings. 
 The observation period for this study was 6-months.  Typically, data is 
reported for continuation at 1-year.  In this study, patients only received the 
intervention once and were followed thereafter by primary care or cardiology.  
Measuring continuation even at 6-months may be reflective of the care patients 
received at some point after participating in BRIDGE.  The median number of 
days from discharge to seeing any provider or cardiology ranged between 15 and 
59 days. 
 A further limitation of this study was the use of self-report data for 
medication adherence.  Discharge prescribing rates were obtained directly from 
the discharge note on the patient’s electronic medical record.  However, 
persistence data were obtained from clinic notes and reflected what the patient 
reported when interviewed.  No pharmacy data or pill counts were done.  For 
those who discontinued their medication, information as to whether this was a 
patient or provider decision was generally not documented.  Self-report was a 
practical means of collecting this retrospective data.  Even with IRB approval and 
resources, contacting patients for a more formal recollection of their persistence 
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in the past would not have provided accurate data.   It has been shown that self-
report adherence correlates with pill counts and blood pressure control (Haynes 
et al., 1980; Yiannakopoulou, Papadopulos, Cokkinos, & Mountokalakis, 2005) 
and is most accurate over the short term rather than the long term (Jerant, 
DiMatteo, Arnsten, Moore-Hill, & Franks, 2008).  Moreover, self-reported 
medication non-adherence with cardiovascular agents is strongly associated with 
adverse cardiac events (Gehi, Ali, Na, & Whooley, 2007).  It is not possible to 
determine whether use of this methodology over or underestimates the potential 
benefits of BRIDGE.  A more formal study is warranted to investigate these 
findings as well as influences of racial, ethnic, gender, and socioeconomic 
diversity. 
Conclusion 
 These findings suggest that attendance in a one-time, ambulatory, NP-
based transitional care program may improve medication persistence.  
Demographic variables, comorbidities, health status (CCI) and severity of event 
(GRACE Risk Score) were all examined and did not explain these findings, 
although some studies have shown that education and support from healthcare 
providers has a positive effect on medication behavior (Burke, Dunbar-Jacob, & 
Hill, 1997; Eagle, Kline-Rogers, et al., 2004; Haynes, McKibbon, & Kanani, 
1996).  Nurse practitioners are well suited to provide the type of high-level, high-
quality care that ACS patients require (Albert, 2008).   
 The BRIDGE program was developed from a medical model utilizing NPs.  
Differences in NP and medical training may account for variations in practice and 
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in how information is obtained and delivered during a visit (Albert, 2008; Horrocks 
et al., 2002).  NPs of the BRIDGE program deliver high quality, cost effective 
care in a manner consistent with the Information, Motivation, Behavior Model.   
(Fisher et al., 2008; Fisher & Fisher, 2002; Fisher & Fisher, 2003).   
This theoretical framework suggests that patients seen in the BRIDGE clinic 
should have higher rates of persistence on combined pharmacotherapy six-
months after discharge.  Through education, NPs influence patients’ attitudes 
and beliefs related to their ability to take preventative medications and the 
positive benefits of doing so.  By enabling patients to develop the skills 
necessary to initiate and maintain positive behavior, it is expected that patients 
receiving this type of one-on-one follow-up will be more persistent with their 
medications than those who do not.   
 As evidence to BRIDGE’s success, participants had greater combined 
pharmacotherapy persistence at 6-months than usual care. Given the 
overwhelming evidence that combined pharmacotherapy is life-saving and that 
medication persistence is a significant issue in ACS patients, further investigation 
is necessary to document how transitional care influences this behavior.  These 
results support the growing body of research demonstrating that transitional care 
not only helps patients navigate an overburdened healthcare system, but also 
has a direct impact on patient behavior and successful outcomes. 
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CHAPTER III 
THE BRIDGE PROGRAM REDUCES HOSPITAL READMISSIONS  
Introduction 
 Hospital readmissions place a considerable burden on an already 
stressed U.S. healthcare system and are a subject of great concern (Jencks et 
al., 2009).  Although there are justifiable reasons for readmissions, many are 
avoidable.   The Centers for Medicare and Medicaid Services monitor and record 
hospital readmission rates for a number of high-risk conditions as these rates are 
considered by many to be a marker of care quality.  Hospital readmissions after 
an acute myocardial infarction (AMI) are among the conditions monitored. 
 It is estimated that 16.3 million Americans already suffer from coronary 
heart disease with a disproportionate number represented by ethnic minorities.  It 
is also estimated that approximately 785,000 Americans will have a new 
coronary event this year from which approximately one-third will die (Roger et al., 
2011).  Of the more than 518,000 who survive, 470,000 (90%) will have a 
recurrent event (Roger et al., 2011).  Despite these sobering statistics, little is 
known about the circumstances surrounding readmissions following an acute 
coronary event (ACS), although there is speculation that contributors to 
readmissions among those patients may include premature discharge, lack of 
prompt access to cardiology follow-up after hospital discharge (Fye, 2004), 
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insufficient discharge education, lack of patient understanding of education 
provided, and poor provider adherence to American Heart Association/American 
College of Cardiology guidelines (AHA/ACC). Many of these contributors appear 
to be problematic during the patient’s transition from hospital to home and the 
imminent shift from direct care to self-care that occurs during this period. 
 The hospital-to-home, or transitional care, phase of the patient care 
continuum begins prior to discharge and terminates once the outpatient care 
team has seen the patient and assumes responsibility for his/her care.  This 
differs from coordinated care, which is a means to ensure that appropriate follow-
up is being planned and carried out.  Transitional care, on the other hand, is an 
actual clinical phase between acute care and ambulatory care with direct patient 
contact.  Both transitional care and coordination of care aim to fluidly move 
patients from the acute care setting to the outpatient setting by facilitating 
communication, discharge education, medication management, resolution of 
outstanding diagnostics, and instruction on when to seek care (Hernandez et al., 
2010).  Coordination of care achieves all of these but lacks direct patient 
evaluation during the intermediate period before ambulatory care providers 
assume responsibility.  Most models of transitional care are built around direct 
patient assessment, diagnosis, treatment, and education during this interim 
phase (Coleman et al., 2006; Naylor et al., 2004; Sinclair et al., 2005; Stewart et 
al., 1998).  
 Transitional care is not a new concept but certainly one that, driven by 
today’s public scrutiny of health policy and finance, has become recently 
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elevated as a key component along the patient care continuum.  Health care 
providers have long recognized the consequences of poor patient follow-up, but 
lack of provider accountability between discharge and ambulatory acceptance 
has allowed the hospital-to-home problem to go largely unchecked until now.  
Since hospital readmissions became a publicized quality indicator of hospital 
performance, transitional care has gained a new following.  Before 2005, 
research and publications on transitional models of care were scarce.  Today, 
there is a national organization (H2H, Hospital-to-Home) working with the 
collaborative input of all levels of health care providers to design and structure 
solutions using this approach. 
 Initially, the aim of reporting hospital readmission rates was aimed to draw 
attention to the dilemma and allow patients to make informed choices about 
where to seek care.  Later, readmission rates became part of a pay-for-
performance program tied to specific conditions such as AMI, heart failure, and 
pneumonia (Conrad & Christianson, 2004).  Now, the Patient Protection and 
Affordable Care Act (ACA) of 2010 is making lower hospital readmission rates an 
expectation.  If this expectation is unmet, hospitals may suffer substantial 
penalties in the form of reductions in reimbursement.  According to the policy, a 
percentage of the institution’s aggregate Medicare payments, not just charges for 
the diagnosis-related group (DRG) where the readmission rate is in “excess,” can 
be withheld by the Centers for Medicare and Medicaid Services (Foster, 2010).  
Initial fines will be imposed in 2013 and will be levied against 2012 readmission 
rates.  In year one of this program, the penalty is 1% of the aggregate Medicare 
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payments.  In year two, 2014, the penalty will increase to 2% and in 2015 to 3% 
(ACA, 2010; refer to the Appendix for an example of how much this will 
potentially cost hospitals).  This timeline has prompted a sense of urgency for 
hospitals and payers to work together toward resolving inherent problems 
associated with increased readmission.  
 The “Bridging the Discharge Gap Effectively” (BRIDGE) program is a 
novel care model that recognizes the growing concern regarding  hospital 
readmissions and the need for care during the critical hospital-to-home transition.  
Now nearing its fifth year of operation, BRIDGE is a nurse practitioner (NP)-
driven model that provides a one-time ambulatory transitional care visit within 14 
days of discharge for patients discharged from a cardiology service or who 
required a cardiology consult during their hospitalization.  
 During that visit, NPs aim to eliminate many of the aforementioned 
contributors to hospital readmissions by providing thorough examinations and 
evaluating each patient’s response to treatment, performing medication 
reconciliation, and making therapeutic adjustments when necessary.  The NPs 
also provide tailored education about the individual’s event, condition, and 
disease process and when to seek follow-up.  Serving more broadly as care 
managers, BRIDGE NPs also review all diagnostic tests from discharge and 
ensure that appropriate diagnostics and follow-up are scheduled for the future.  
The NPs act as an extension of the hospital discharge team, contacting the team 
when necessary.  Still, despite its purpose and five-year history, the efficacy of 
BRIDGE in reducing hospital readmissions for ACS patients is unknown. 
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 The purpose of this study is to determine if there is a difference in hospital 
readmissions following discharge from the hospital for an ACS event, between 
patients who participated in the NP-delivered BRIDGE transitional care program 
and those who had usual care (follow-up post-hospital discharge with primary 
care or cardiology).  It is hypothesized that when compared with patients who 
had usual care, patients who participate in the BRIDGE program will have lower 
rates of hospital readmissions. 
Methods 
Design 
 This retrospective, quasi-experimental study assesses the efficacy of the 
NP-driven BRIDGE program as a model for transitional care.  The 30-day 
readmission rates for ACS patients who participated in the BRIDGE program 
were compared to patients who chose not to participate and received usual care.   
Setting 
 The University of Michigan Health System’s (UMHS) Bridging the 
Discharge Gap Effectively (BRIDGE), as described more thoroughly in chapter 2, 
is a program designed to provide transitional care for patients discharged after an 
ACS event. The clinic is staffed by five specialty-certified cardiovascular nurse 
practitioners who function in collaboration with onsite cardiologists.  Within the 
BRIDGE clinic, the NPs perform physical assessments, assess patient status, 




          As previously described, all patients over 18 years of age discharged from 
the UMHS with a diagnosis of ACS were eligible for this study.  Referrals were 
made to the BRIDGE program based on whether or not a patient had a follow-up 
appointment scheduled with their cardiologist or primary care provider within 14 
days of discharge.  Patients included were discharged between March 30, 2008 
and March 30, 2009 and were divided into two cohorts: those who were referred 
and attended the program and those who were referred and did not attend. 
Patients were excluded from the study if they became pregnant, sought follow-up 
outside of the UMHS, or expired within 30 days of discharge.  The Social 
Security Death Index was queried for patients lost to follow-up. 
 The study cohort included 424 registry eligible patients referred to the 
BRIDGE program.  Acute coronary syndrome (ACS) comprised 25.2% (n=107) of 
the diagnoses of those referred. Patients were excluded if they died or were 
rehospitalized prior to their initial BRIDGE appointment (n=9, 8.4%). The final 
study sample included 80 patients after excluding patients with missing variables 




 As in the prior study examining medication persistence, two separate 
measures were used to describe patient characteristics: the Charlson 
Comorbidity Index (CCI) and the GRACE Risk Score.  The CCI serves as a proxy 
for an individual’s overall state of health or illness.  It has been tested across a 
variety of populations and settings and has been consistently in predicting 
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Figure 5.  Patient flow diagram of analysis of hospital readmissions. 
 88 
comorbid conditions on mortality, where higher scores are associated with higher 
mortality (Charlson et al., 1987; Charlson et al., 1994).  The GRACE Risk Model 
for discharge predicts the risk of death in patients with ACS from hospital 
discharge to six months out.  In this study, the GRACE Risk score is indicative of 
the severity of the individual’s event.  Nine items are included in this multivariate 
prediction model and have demonstrated a c-statistic between 0.70 and 0.80 
(Eagle, Lim, et al., 2004).  The discriminatory and predictive validity of this tool 
has been widely published (Elbarouni et al., 2009; Ramsay et al., 2007).  
Approach 
 Specifics of the design and maintenance of the BRIDGE registry were 
presented in chapters 1 and 2.  Briefly, consecutive data for all patients referred 
to the BRIDGE program was collected into a de-identified, online, clinical 
database maintained by the Michigan Cardiovascular Outcomes Research and 
Reporting Program (M-CORRP).   
 Data were collected using the abstraction form shown in chapter 1, Figure 
3.  The variables included basic demographics, admission data, discharge data, 
and 6-month follow-up data. Detailed information pertaining to medications and 
items necessary to calculate the CCI score and GRACE Risk Score were also 
incorporated.   
Data Analysis 
General.  Data were analyzed using PASW 18.0.  All variables were 
assessed for compliance with statistical assumptions including normal 
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distribution.  Skewed data were transformed as necessary before inclusion into 
any model.  Missing data were excluded from the sample. 
 Univariate and bivariate analyses.  Baseline equivalencies were 
assessed for all demographic variables, comorbidities, CCI scores and GRACE 
Risk Scores.  Associations between variables were assessed with Pearson’s 
correlation coefficient.  Independent student t-tests (continuous variables) and 
Chi Square (categorical variables) were used to compare the BRIDGE 
intervention group and the control group.  Pearson’s Chi-square test for 
significance was reported except in cases where the expected count would 
violate an underlying assumption; in these cases, Fisher’s Exact test was 
reported.  The significance level was set at 0.05 for all analyses.  
Readmission rate.  The hospital readmission rate was calculated as the 
number of patients discharged from the hospital with a diagnosis of an ACS 
event and readmitted to UMHS within 30 days, divided by the total number of 
people who were discharged alive with the same diagnosis (Jencks, et al., 2009).  
In order to isolate the BRIDGE effect, patients who were readmitted or died prior 
to their initial BRIDGE appointment date were excluded.  The BRIDGE and non-
BRIDGE specific rates of readmission were calculated as the total number of 
readmissions for the BRIDGE and non-BRIDGE groups divided by the total 
number of subjects in each group.  Only the first readmission following discharge 




 Of 107 ACS patients discharged from UMHS and referred for follow-up 
with BRIDGE, 80 were included in the final sample.  Patients who died or were 
readmitted prior to their BRIDGE appointment were excluded, as were patients 
with missing data (n=27, refer back to Figure 5).  Excluded patients were 
compared to patients remaining in the study (see Table 6).  The patients 
excluded from the sample were noted to have higher CCI and GRACE Risk 
scores, suggesting that these patients either had more comorbid conditions, 
worse events, or both. 
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Table 6 





All Others  
n=98 (91.6%) p-value 
Age (mean +SD) 66.09 (14.96) 62.4 (13.9) .409 
Gender (% Female) 4 (44.4) 59 (60.2) .483 
Race    
White 7 (77.8) 83 (85.6) .622 
Non-white (Black, Asian,  
Native American, Hispanic)  
2 (22.2) 15 (14.4) .622 
Comorbidities    
Afib 1 (11.1) 7 (7.1) .517 
CVD 0 6 (6.1) 1.00 
Hx TIA 0 2 (2.0) 1.00 
Hx CVA 0 2 (2.0) 1.00 
CHF 2 (22.2) 12 (12.2) .334 
CAD 9 (100) 91 (92.9) 1.00 
Current Smoker 2 (22.2) 24 (24.5) 1.00 
Diabetes 3 (33.3) 30 (30.6) 1.00 
Dyslipidemia 5 (55.6) 71 (72.4) .279 
HTN 7 (77.8) 63 (64.3) .493 
Obesity 1 (11.1) 18 (18.4) 1.00 
Peripheral Vascular  1 (11.1) 12 (12.2) 1.00 
Psychiatric Disorder n=35 (32.7%) n=4 (44.4%) n=31 (31.6%)  
Anxiety 1 (25.0) 16 (51.6) .603 
Dementia 1 (25.0) 5 (16.1) .546 
Depression 3 (75.0) 24 (77.4) 1.00 
Substance 0 8 (25.8) .553 
Charlson Comorbidity  5.43+-2.30 3.98 +-1.79 .015 
GRACE Risk Score 123.00+-37.53 99.69+-30.79 .022 




 The mean age of all study participants was 62.5 years.  The majority 
(58.7%) were female, and white (86.3%) with a median length of initial hospital 
stay ranging from 2-4 days.  Table 7 shows a comparison of patients who 
attended BRIDGE versus those who did not.  With the exception of a higher 
percentage of dyslipidemia among BRIDGE users and slightly elevated rates of 
depression among non-attenders, there were no significant differences between 
the two groups. 
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Table 7 




Did Not Attend  
n=18 (22.5%) p-value 
Age (mean +SD) 62.9+14.1 60.9+14.8 0.596 
Gender (% Female) 35 (56.5) 12 (66.7) 0.438 
Race    
White 53 (85.5) 16 (88.9) 1.00 
Non-white (Black, Asian,  
Native American, Hispanic)  
9 (14.5) 2 (11.1) 1.00 
Comorbidities    
Afib 4 (6.5) 1 (5.6) 1.00 
CVD 4 (6.5) 0  0.570 
Hx TIA 2 (2.8) 0 (0) 1.00 
Hx CVA 1 (1.6) 0 1.00 
CHF 7 (11.3) 4 (22.2) 0.256 
CAD 59 (95.2) 18 (100.0) 1.00 
Current Smoker 16 (25.8) 3 (16.7) 0.539 
Diabetes 2 (32.3) 4 (22.2) 0.413 
Dyslipidemia 49 (79.0) 9 (50.) 0.033 
HTN 41 (66.1) 9 (50.0) 0.213 
Obesity 13 (21.0) 1 (5.6) 0.172 
Peripheral Vascular  5 (8.1) 4 (22.2) 0.109 
Psychiatric Disorder n=27 (43.5%) n=17 (27.4) n=10 (55.6%)  
Anxiety 9 (52.9) 5 (50.0) 1.00 
Dementia 3 (17.6) 1 (10.0) 1.00 
Depression 12 (70.6) 8 (80.0) 0.678 
Substance 4 (23.5) 2 (20.0) 1.00 
GRACE Risk Score 100.8+30.9 104.8+32.9 0.527 
Charlson Comorbidity  4.05+1.74 3.98 +1.96 0.745 
 94 
Attendance 
 As seen in Table 6, 77.5% (n=62) of the patient’s referred to the BRIDGE 
program attended their scheduled appointment.  The median time from discharge 
to attending a BRIDGE program appointment was 15 days (see Figure 6).  The 
time elapsed between discharge and being seen by any medical provider was 
longer  (20 days) for patients who did not attend BRIDGE.  However, patients 
who did not attend BRIDGE were also seen by cardiology sooner (31 days 
versus 59 days).  Consistent with these findings, patients contacted by phone for 
a missed or cancelled appointment (n=58) reported that the primary reason for 
not attending was getting an earlier appointment with either cardiology or their 
primary care provider (34.5%).
 
Figure 6.  Mean days to follow-up (data from full registry). 















It was hypothesized that patients who took advantage of the BRIDGE 
program would have lower readmission rates than patients who received usual 
care.  In fact, as shown in Figure 7, patients who attended the BRIDGE program 
had lower rates of readmission at 30, 60, 90, and 180 days after hospital 
discharge for an ACS event than did non-attenders. 
 Patients participating in the BRIDGE program, moreover, had an 
unadjusted risk of readmission between .200-.378 compared to usual care (see 
Table 8).  Data were adjusted independently for patients’ overall health by the 
Charlson Comorbidity index and for the severity of their event using the GRACE 
Risk Score on discharge.  Because these two measures had a linear relationship 
with an r-value of .812, they could not be used simultaneously in a model.  




























Figure 7.  Readmission rates for BRIDGE attenders versus non-attenders. 
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benefit.  The adjustment with either CCI or GRACE demonstrated poor model 
calibration with nonsignificant Hosmer and Lemeshow tests.   
Table 8 
Odds of Being Readmitted 30, 60, 90, and 180 Days After Discharge for 
Patients Who Participated in the BRIDGE Program. 
Days after 
DC  OR  95% CI 
Adjusted 
OR  CCI 95% CI 
Adjusted  
OR GRACE  95% CI 
30 Days .179 .042-.761 .268 .069-1.038 .285 .075-1.091 
60 Days .138* .037-.514 .191* .054-.669 .203* .059-.699 
90 Days .233* .007-.776 .268* .078-.922 .306 .093-1.009 
180 Days .378 .128-1.112 .311 .095-1.021 .373 .119-1.167 
*p-value <0.05 
 The forest plot below (Figure 8) shows the unadjusted odds of being 
readmitted if the patient attended his BRIDGE appointment.  At 60-days post-
discharge patients were significantly less likely to be readmitted though at all 
points post-discharge there was a trend towards being less likely to be 
readmitted.  The effect appears to diminish over time as might be expected 
subsequent to a single-dose intervention. 
Figure 8.  Unadjusted odds of readmission with BRIDGE participation. 
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Discussion 
 It was hypothesized that when compared with patients who had usual 
care, BRIDGE participants would have lower rates of hospital readmissions.  This 
study found that the NP-driven, single-dose, transitional care program was an 
effective strategy to lower all-cause hospital readmissions for ACS patients.  
Even with adjustments for severity of illness and severity of event, patients who 
chose to attend their BRIDGE appointments fared better than patients who 
received high-level, evidence-based usual care.  Although this study was 
designed to address readmissions within 30-days of hospital discharge, the 
maximum benefit was observed 60-days post discharge with a positive trend at 
all other time points.  
Limitations 
 The design of this program is straight forward, and the results are positive.  
However, there are some limitations that should be considered with regard to this 
study.  Study data were collected retrospectively.  As a result, causality may not 
be assumed.  There is the potential that unmeasured variables may be 
confounding the results.  As previously stated, this study was conducted via an 
observational registry and lacks randomization. Patients chose whether or not to 
attend and the resulting groups were not necessarily equivalent.  Therefore, the 
results may not be generalizable.  Usual care at the study institution has a high 
rate of compliance with evidence-based therapies and thereby sets the bar 
higher for significance to be found.   
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 The sample size for this study is small particularly for those receiving 
usual care.  Despite the registry having over 500 patients, after exclusions and 
limitations of the data, the final sample included only 80 cases that met the study 
criteria.  With such a small beginning sample and outcome rates as low as 9.7%, 
there was an insufficient number of outcomes to adequately power a multiple 
regression analysis.  Despite the small sample size, significance was established 
at both 60 and 90-days post discharge. With a larger sample, it is likely that there 
would have been a significant difference at 30-days post discharge as well.  
Patients with missing follow-up data were excluded from the study.   
 Consistent with the institution’s high level of care, when the BRIDGE 
program began (2008), post-discharge follow-up within 14 days was a 
reasonable standard.  Today, follow-up time frame recommendations may be for 
as early as 7 days post-discharge (Hernandez et al., 2010).   Although there are 
published guidelines for recommended follow-up times for heart failure patients, 
little research exists regarding follow-up for patients with AMI or ACS.  
Conducting the BRIDGE intervention at day 14 post-discharge was problematic 
for monitoring 30-day outcomes.  Because patients with adverse events prior to 
the BRIDGE appointment were excluded from the study, the program truly only 
evaluated the later half of the 30-day measuring period.  Adjusting the time to 
follow-up date might have a significant impact on findings in the future.  
Comparing those who were excluded for early adverse events to the final study 
sample revealed one significant difference: patients with early adverse events 
had higher Charlson Comorbidity Scores.  The CCI for the study population was 
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3.98.  The CCI for patients with early adverse events was 5.43.  These patients 
had nearly a 35% increase risk of mortality in the first year (Charlson et al., 
1987).    
Conclusion 
 The general cardiology BRIDGE program is a novel solution to implement 
a transitional care program.  This NP-based model is an effective strategy to 
improve patient care quality and reduce hospital readmissions.  The NPs provide 
a high level of service ensuring the health of their patients, providing education to 
the patients and their families, reconciling medications, and communicating with 
the patient’s discharge team and outpatient care provider. Patients who 
participated in this program had a trend toward lower readmission rates at 30, 90, 
and 180-days post discharge than those who opted for usual care.  The 
observation of a significant reduction in readmission rates at 60-days post-
discharge for BRIDGE attendees provides further support for the effectiveness of 
the intervention.  The median time-from discharge to follow-up with a cardiologist 
for BRIDGE participants was 59 days.  The median time for follow-up with a 
cardiologist for usual care was 31 days.  The lower 60-day readmission rate 
reflects how the BRIDGE intervention fared against a high level of usual care 







THE BRIDGE PROGRAM IS COST EFFECTIVE 
Introduction 
Readmission rates following hospital discharge for a cardiac condition are 
both common and costly.  In the absence of efficient and effective transitional 
care, nearly 20% of all Medicare patients discharged will be rehospitalized within 
30 days (Krumholz et al., 2009). Half of those readmitted will be patients who 
have had no contact with a healthcare provider since their discharge (Jencks, 
Williams, & Coleman, 2009).  The cost of unexpected readmissions exceeded 17 
billion dollars in 2004 (Jencks et al., 2009; Krumholz et al., 2009).  From a 
societal perspective, this is of significant concern for our financially troubled 
healthcare system. As a matter of policy, legislation has been passed to further 
penalize hospitals for excessive readmissions.  
Readmission rates are of particular concern in cardiovascular disease 
(CVD) where readmissions meet or exceed the national average for all Medicare 
beneficiaries.  Cardiovascular disease (CVD) is the leading cause of death in the 
United States (US) with more than 1 out of every 3 adult Americans afflicted in 
some manner (Centers for Disease Control and Prevention, 2011).  Not only 
does CVD carry the highest mortality rate, but cardiac diagnoses are associated 
with substantial morbidity, disability, and hospital utilization and account for the 
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highest number of hospital discharges. Considering the prediction that Americans 
will suffer approximately 785,000 first coronary events this year and that a further 
470,000 will experience a recurrent event (Roger et al., 2011), there may be 
nearly a half-million rehospitalizations from coronary events (assuming they all 
are hospitalized).  These numbers provide for an ideal opportunity to develop 
transitional care interventions for a well-defined population with exceptional 
evidence-based therapies for secondary prevention.  These interventions may be 
further prompted by legislation that will bundle payments for patients readmitted 
after discharge from acute myocardial infarctions (AMI), heart failure or 
pneumonia (Patient Protection and Affordable Care Act of 2010). 
Improving the hospital-to-home transition is paramount to reducing 
readmissions for patients suffering from acute coronary syndromes (ACS) such 
as ST-elevated myocardial infarction, nonST-elevated myocardial infarction, and 
unstable angina.   Ideally, the cost of such programs can be offset by avoided 
readmissions.  However, few transitional care studies have reported their overall 
effect in this way.  For example, Coleman, Parry, Chalmers and Min (2006) 
conducted a randomized trial of 750 patients with a variety of medical diagnoses. 
Study participants in the intervention arm received tools to promote cross-site 
communication among providers, were encouraged to take a more active and 
assertive role in their care, and were provided with a “transitional coach” to follow 
their progress; control subjects received usual care.  Outcomes revealed that 
mean hospital costs were $488 lower for the intervention group 180-days post-
discharge when compared to those receiving usual services.  Another program, 
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funded by the Agency on Healthcare Research and Quality (AHRQ), and now 
endorsed by the Joint Commission Resources, implemented a similar design in 
their “Re-Engineered Discharge” or Project Red Model (Project Red [Re-
engineered Discharge], 2011).   By designating a “discharge advocate” to work 
with each patient, tailoring discharge booklets to each individual (designed for the 
program), and asking a clinical pharmacist to do a telephone follow-up 2-4 days 
after discharge, the project demonstrated reductions in hospital utilization and a 
per-patient savings of $412.  Krumholz et al. (2002) randomized 88 heart failure 
patients to receive a one hour face-to-face education session within 2-weeks of 
hospital discharge (45% of which were in-home visits) followed by 4 weekly 
telemonitoring calls.  The study concluded that the combination of education and 
phone follow-up substantially reduced adverse events after discharge and 
reduced readmission costs by $7,515 per patient.  Naylor et al. (2004) 
demonstrated that a 3-month comprehensive NP-driven, in-home, transitional 
care program for elders with heart failure, decreased readmissions and lowered 
healthcare costs.  In this program, patients were visited daily in the hospital and 
provided education.  Following discharge, patients received at least eight home 
visits during the first 90 days after discharge and the NPs were available by 
telephone daily.   
Patient education on secondary prevention measures is the most common 
theme among transitional care programs.  In addition to diet and lifestyle 
modifications, keeping patients on a multidrug regimen of beta-adrenergic 
blocking agents [ß-blockers], angiotensin converting enzyme inhibitors [ACE-
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inhibitors] or angiotensin receptor blocking agents [ARBs] in patients intolerant to 
ACE-inhibitors, aspirin, HMG-CoA reductase inhibitors [statins], and clopidogrel 
for up to 1 year post-event (combined pharmacotherapy) is essential.  This 
evidence-based combination drug regimen is the key to avoiding future events 
and maintaining homeostasis for ACS patients (Antman et al., 2009; Smith Jr et 
al., 2006).  The co-administration of these agents is estimated to reduce post-
event mortality by between 72 and 87% (Hippisley-Cox & Coupland, 2005; 
Mukherjee et al., 2004; Wald & Law, 2003).  Despite the accomplishments of 
these programs and many others, no single intervention has been successful 
enough to garner overwhelming support from the healthcare delivery system at 
large (Jencks et al., 2009).  Part of the lack of acceptance is a paucity of data to 
determine whether these programs are quality effective and cost effective, 
particularly as they relate to hospital readmissions. 
To conduct a successful cost analysis pertaining to hospital readmissions, 
it is essential to understand the multiple perspectives of this phenomenon and 
those of this study.  A societal view of hospital readmissions, for example, 
assumes that lower readmission costs are a benefit to society and the overall 
health care system.  An institutional view, on the other hand, might consider 
lower readmissions as generating less revenue (at least until hospitals are 
penalized for readmissions).  The perspective of an insurance company is more 
complicated and requires weighing the cost of hospitalization against the cost of 
long-term outpatient therapies.  From a patient’s perspective, the cost of a 
hospital readmission is reinforced by the quality of life (i.e. staying home with 
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family and or being with friends) they receive in return.  The perspective of this 
study parallels the societal perspective: that fewer hospital readmissions are a 
benefit.   
After understanding the perspective of a cost analysis, the next 
requirement involves defining the actual costs of an intervention and determining 
how data can be obtained.  In determining the cost of a nurse practitioner (NP)-
led transitional care visit, for example more than just the nurses’ salaries must be 
taken into consideration. The true cost involves the amount of time devoted to 
each patient, the space used for the NP patient consultation, as well as support 
staff salaries and supply costs.  The ultimate goal is to capture all costs that are 
associated with the ability for the patient to be seen at a clinic and for the NP to 
provide needed care. 
 Compared to usual care, the NP-driven transitional care model Bridging 
the Discharge Gap Effectively (BRIDGE), as previously described, reduced 
hospital readmissions by 18.1%.  This reduction was reported in chapter 3, and 
was derived by comparing actual rates of readmission 30-days post discharge for 
BRIDGE participants against those receiving usual care. To determine if there is 
a cost savings in providing this type of transitional care to ACS patients, the costs 
of BRIDGE were compared against avoided readmission costs.  It was 




As previously described, this study included consecutive patients 
discharged from UMHS after an ACS event.   Demographic, clinical, and follow-
up data were collected retrospectively on all patients referred to BRIDGE from 
March 2008 to March 2009. Patients readmitted before their BRIDGE 
appointment were excluded from the study. 
Setting 
 Bridging the Discharge Gap Effectively is a nurse practitioner (NP)-based 
program nested within an existing cardiology practice.  The BRIDGE program is 
designed to ensure that patients who are discharged after an ACS event have 
support throughout the hospital-to-home transition. The clinic is staffed by five, 
specialized, cardiovascular nurse practitioners who function in collaboration with 
onsite cardiologists.   
Sample 
 As described in chapter 3, the study cohort included 424 registry eligible 
patients referred to the BRIDGE program.  Included in this study were individuals 
diagnosed with ACS (n=107), which comprised 25.2% of the referrals.  Patients 
with an early adverse event (EAE) who died or were rehospitalized prior to their 
initial BRIDGE appointment were excluded from the final sample (n=9). The final 
study sample included 80 patients after removing 18 patients with missing data 




 Being seen in the BRIDGE clinic is the intervention in this study.  Five 
specially trained cardiology nurse practitioners independently provided care and 
support in the BRIDGE clinic as an extension of the discharge team.  The NPs 
performed complete physical assessments and medication reconciliation, 
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Figure 9.  Patient flow diagram for analysis of cost avoidance from readmissions. 
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They ensured that the American College of Cardiology/American Heart 
Association guidelines for secondary prevention medications were met. 
Measures 
 Consistent with the analyses presented in chapters 2 and 3, two separate 
measures were used to evaluate subjects’ state of health and severity of disease.  
The Charlson Comorbidity Index (CCI) served as a measure of an individual’s 
state of health or illness (Charlson et al., 1987; Charlson et al., 1994).   This is a 
well established tool, found to be a valid for predicting mortality (Needham et al., 
2005).  The GRACE Risk Model for discharge is a tool to predict the risk of death 
in patients with ACS from discharge to six months out and provided a means to 
quantify the severity of the subject’s event.  The discriminatory and predictive 
validity of this tool are widely published (Elbarouni et al., 2009; Ramsay et al., 
2007). 
Approach 
 Full descriptions of the development, maintenance and registry methods 
are described in chapters 1 and 2.  In summary, consecutive data for all patients 
referred to the BRIDGE program were collected into a de-identified, online, 
clinical database.  Basic demographics, admission data, discharge data, and 6-
month follow-up data were collected including detailed information pertaining to 
medications and variables to calculate the CCI score and the GRACE Risk 
Score.   
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Data Analysis 
 Summary statistics for baseline characteristics were reported as means 
and standard deviations for continuous variables, and percentages for 
categorical variables.  Group comparisons were made using independent-
samples t-test for continuous variables, and Pearson chi-squared or Fisher’s 
Exact Test for categorical variables.  All variables were assessed for compliance 
with statistical assumptions.  Missing data were excluded from the sample.  Data 
were analyzed using PASW 18.0.   
Cost Analysis 
 A cost analysis was performed comparing BRIDGE costs against avoided 
30-day hospital readmissions between patients who participated in the BRIDGE 
program and patients who had usual care.  
 The BRIDGE clinic operates on a variable (per patient) cost basis.  To 
assess the per patient cost or savings of the BRIDGE program, the difference in 
observed readmission rates for participants and nonparticipants was multiplied 
by the average cost of a cardiac readmission (MS-DRGs 283-316) and deducted 
from the cost of an individual BRIDGE visit.  Overall program savings was 
determined by calculating the additional readmission costs that would have 
resulted if participants had been readmitted at the same rate as nonparticipants 
and then deducting the cost of their BRIDGE visits. 
 Incremental Costs.  Incremental patient costs including personnel costs 
and overhead costs were obtained from institutional administrative data for the 
2010 fiscal year (D. E. Karpenko, personal communication, October 5, 2010).  
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NP and medical assistant (MA) salaries were reported as hourly rates (see Table 
8).  The first 2 months of the fiscal year 2010 were utilized to develop the model 
for analysis, as these were the most current and available data. 
 NP and MA rates were inflated by 30.0% and 32.5% respectively (based 
on institutional pay scales) for fringe benefits.  The cost of space is based on 
square footage and includes utilities and maintenance.  Room costs were 
calculated on an average of 260-work days per year and multiplied by 40% for 
the utilization of associated spaces (reception, waiting room, and check out).  
Supply costs were derived by dividing the supply costs for the entire clinic, by the 
total number of clinic visits during the same period.   
 To interpret the data in Table 8, begin by looking at the hourly rates for the 
NP and MA.  Prorate these figures by the amount of time allocated for the care of 
one patient.  In this case, the model allowed for 30 minutes of NP time and 10 
minutes of MA time (to put patients in rooms and obtain vital signs) for each 
patient.  Per clinic protocol, NPs were scheduled for 30 minutes (which includes 
dictation time) with each patient.  MAs spend on average 10 minutes with 
patients situating them in rooms and collecting vital signs.  Add to this the 
prorated room rental fee for 30 minutes and the per-person supply cost.  The 




Variable Per-Patient Costs for the BRIDGE Program 
Variable Cost  Unit Amount utilized Cost per-patient visit 
Nurse Practitioner $64.76 60 minutes 30 minutes $32.38 
Medical Assistant $20.20 60 minutes 10 minutes $3.30 
Room $20.68 Day 30 minutes $1.15 
Supplies $7.02 Visit -- $7.02 
TOTAL COST PER-PATIENT PER APPOINTMENT $43.85 
 
 Model inputs.  Table 9 shows a summary of the model inputs for this 
analysis.  In addition to the cost of a BRIDGE visit, this model additionally 
requires readmission rates and hospitalization costs. 
 Readmission costs.  The average cost for an inpatient cardiology 
admission for the MS-DRGs 283-316 (AMI, circulation disorders, endocarditis, 
heart failure, cardiac arrest, peripheral vascular disease, atherosclerosis, 
hypertension, valve disorders, arrhythmias, angina, syncope, and chest pain) 
was obtained from the American Hospital Directory (see Table 10).  The 
American Hospital Directory is an analysis group that provides data from the 
Medicare Provider Analysis and Review (MedPAR) database that enables 
institutions to benchmark financial information, quality, and outcomes against 
other institutions.  MedPAR is updated annually and contains 100% of the billing 
data for Medicare fee-for-service claims for hospital discharges (American 
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Hospital Directory, 2011).  The average charge is from the study institution for 
the fiscal year ending September 30, 2009.    








 Range Tested Source for Data 
Cost 
BRIDGE visit  $43.85a $0 25%-200% From Table 9 
Readmission  $27,558b $27,558b 25%-200% 
American hospital 
directory 2011 
Observed readmission probabilities 
30 Day  9.7% 27.8% 25%-200% Observed data 
60 Day 11.3% 38.9% 25%-200% Observed data 
aFrom Table 9     
bAverage cost of a cardiology admission based on MedPar data  
 Probabilities.  Readmission rates for BRIDGE and nonBRIDGE 
participants were calculated in an earlier study presented in chapter 3 (refer 
above to Table 10). 
Sensitivity Analysis 
 To assess the stability of the model, a 1-way sensitivity analysis was 
performed.  Because there is a degree of uncertainty associated with the model 
inputs and insufficient data to adequately establish upper and lower limits of 
each, inputs were widely varied (Manning, Fryback, & Weinstein, 1996).  Each 
input was varied 25%-200% consistent with ranges in the literature (Choudhry et 
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al., 2007; Choudhry et al., 2008; Dhalla, Smith, Choudhry, & Denburg, 2009) to 
estimate the degree to which the model parameters influenced the results.  This 
range provides conservative estimates of the best and worst case scenarios at a 
level consistent with values utilized in current literature.   
Results 
Sample 
 Of 107 patients included in this study the mean age was 62.5 years, with 
the majority being white (86.3%) and female (58.7%).  Nine patients were 
excluded from the study due to having an early adverse event and 18 patients 
were excluded because of missing data.  Overall, 77.0% (n=62) of referred 
patients attended their scheduled BRIDGE program appointment (refer back to 
Figure 9).  There were no significant differences in demographics or 
comorbidities between patients who were excluded from the study (see Table 11) 
nor were there differences between patients who received usual care and those 
who participated in the BRIDGE program (see Table 12).  The median length of 
initial hospital stay was 3 days, ranging from 2-4 days.  
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Table 11 





All Others  
n=98 (91.6%) p-value 
Age (mean +SD) 66.09 (14.96) 62.4 (13.9) .409 
Gender (% Female) 4 (44.4) 59 (60.2) .483 
Race    
White 7 (77.8) 83 (85.6) .622 
Non-white (Black, Asian,  
Native American, Hispanic)  
2 (22.2) 15 (14.4) .622 
Comorbidities    
Afib 1 (11.1) 7 (7.1) .517 
CVD 0 6 (6.1) 1.00 
Hx TIA 0 2 (2.0) 1.00 
Hx CVA 0 2 (2.0) 1.00 
CHF 2 (22.2) 12 (12.2) .334 
CAD 9 (100) 91 (92.9) 1.00 
Current Smoker 2 (22.2) 24 (24.5) 1.00 
Diabetes 3 (33.3) 30 (30.6) 1.00 
Dyslipidemia 5 (55.6) 71 (72.4) .279 
HTN 7 (77.8) 63 (64.3) .493 
Obesity 1 (11.1) 18 (18.4) 1.00 
Peripheral Vascular  1 (11.1) 12 (12.2) 1.00 
Psychiatric Disorder n=35 (32.7%) n=4 (44.4%) n=31 (31.6%)  
Anxiety 1 (25.0) 16 (51.6) .603 
Dementia 1 (25.0) 5 (16.1) .546 
Depression 3 (75.0) 24 (77.4) 1.00 
Substance 0 8 (25.8) .553 
Charlson Comorbidity  5.43+-2.30 3.98 +-1.79 .015 
GRACE Risk Score 123.00+-37.53 99.69+-30.79 .022 
aEarly adverse events (hospital readmission or death before BRIDGE appointment). 
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Table 12 




Did Not Attend  
n=18 (22.5%) p-value 
Age (mean +SD) 62.9+14.1 60.9+14.8 0.596 
Gender (% Male) 27 (43.5) 6 (33.3) 0.438 
Race    
White 53 (85.5) 16 (88.9) 1.00 
Non-white (Black, Asian,  
Native American, Hispanic)  
9 (14.5) 2 (11.1) 1.00 
Comorbidities    
Afib 4 (6.5) 1 (5.6) 1.00 
CVD 4 (6.5) 0  0.570 
Hx TIA 2 (2.8) 0 (0) 1.00 
Hx CVA 1 (1.6) 0 1.00 
CHF 7 (11.3) 4 (22.2) 0.256 
CAD 59 (95.2) 18 (100.0) 1.00 
Current Smoker 16 (25.8) 3 (16.7) 0.539 
Diabetes 2 (32.3) 4 (22.2) 0.413 
Dyslipidemia 49 (79.0) 9 (50.) 0.033 
HTN 41 (66.1) 9 (50.0) 0.213 
Obesity 13 (21.0) 1 (5.6) 0.172 
Peripheral Vascular  5 (8.1) 4 (22.2) 0.109 
Psychiatric Disorder n=27 (43.5%) n=17 (24.7%) n=10 (55.6%)  
Anxiety 9 (52.9) 5 (50.0) 1.00 
Dementia 3 (17.6) 1 (10.0) 1.00 
Depression 12 (70.6) 8 (80.0) 0.678 
Substance 4 (23.5) 2 (20.0) 1.00 
GRACE Risk Score 100.8+30.9 104.8+32.9 0.527 
Charlson Comorbidity  4.05+1.74 3.98 +1.96 0.745 
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Readmissions 
Chapter 3 evaluated the differences in readmission rates between patients 
who attended the BRIDGE program and those who received usual care.  ACS 
patients who attended had significantly lower rates of readmission at 30, 60, 90, 
and 180 days post-hospital discharge (see Figure 10).  This analysis builds on 
those findings.   
Cost  
 It was hypothesized that, when compared with usual care, there would be 
a cost reduction in care associated with participation in the BRIDGE program in 
avoided readmissions.  In fact, BRIDGE participants were 18.1% less likely to be 
readmitted 30 days post-discharge, 27.6% less likely to be readmitted at 60 days, 
and 22.8% and 22.6% less likely to be readmitted at 60 days and 180-days 




























Figure 10.  Readmission rates for BRIDGE and non-BRIDGE participants. 
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Table 10) was $43.85 per-patient compared to the average Medicare charge for 
a cardiology admission of $27,558 (American Hospital Directory, 2011). The 
reduction in expected 30-day readmissions for BRIDGE patients compared to the 
incremental BRIDGE costs, translated into a $4,944 per-patient savings, or an 
overall program savings of $306,537.  Savings as a result of avoided 
readmission within 60 days of discharge were even greater (see Table 13).  The 
difference between groups was 9.5% greater at 60 days post-discharge than at 
30 days post-discharge.  This change resulted in an additional 35% savings in 
avoided readmission costs ($121, 286). 
Table 13 
BRIDGE Savings 
 Base Case 
30-Day Readmission  
Per Patient Savings $4,944a 
Program Savings $306,537b 
60-Day Readmission  
Per Patient Savings $7,562a 
Program Savings $468,854b 
a [BRIDGE Cost – ([Probability readmitnonattend-Probability readmitattend ]*Readmit 
Cost)] 
b[(nattend*Probability readmitnonattend*Readmit Cost) – (nattend*Probability 




 One-way sensitivity analyses were performed on the base case for both 
per-patient and programmatic savings.  These findings were robust to a wide 
range of variation in model inputs.  At 30 days post-discharge, there was a per-
patient savings across all of the variations for model inputs (see Figure 11).  The 
cost of the BRIDGE visit had little influence on patient savings, whereas, 
variations in the absolute difference in admission rates between BRIDGE and 
usual care participants and in the cost of readmission both largely impacted 
patient savings.  When readmission costs are extremely high, or when the gap 
between participants and nonparticipants is at its highest extreme, the most 
benefit is observed. 
Figure 11.  Tornado plot showing one-way sensitivity analysis for 30-day per-patient 
savings in the base case. 
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 Overall program savings behaved similar to per-patient savings (see 
Figure 12).  However, programmatic savings rely on applying the rate of 
readmissions from nonparticipants to those who participated in the BRIDGE 
program and calculating additional avoided readmission costs if all of those 
patients had been readmitted.  Therefore, rates of readmission for each group 
were varied instead of simply reflecting the difference between groups.  Again, 
the actual BRIDGE cost had only a small impact on total program savings.  
Readmission rates of nonparticipants and the cost of readmission had the widest 
variation.  When the cost of readmission is at its highest extreme, program costs 
are also at their maximum.  The program only becomes less effective as the rate 
of readmission for nonattendees decreases and approaches the rate of 
readmission of attendees.  Only when the rate of readmission of nonattendees is 
lower than the rate of readmission of BRIDGE attendees does the program 
actually have a cost.   
Figure 12.  Tornado plot showing one-way sensitivity analysis for 30-day program 
savings in the base case. 
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Discussion 
These results highlight the benefits of the BRIDGE program and support 
the hypothesis that the BRIDGE program provides a significant savings in 
avoided hospital readmissions when compared to usual care.  The analysis 
demonstrated that the BRIDGE model reduces health care costs associated with 
readmissions that are in excess of intervention costs.  On average there was a 
per-patient savings of $4,944 in avoided readmissions within 30 days of hospital 
discharge.  Over the duration of the program, this equates to a $306,537 savings 
with ACS patients.  If the BRIDGE transitional care program became the 
standard of care for just these patients, this could result in a societal savings to 
the healthcare system of more than 1.6 billion dollars per year.  Of course, this 
assumes that the rate is based on using the same formula, program costs, 
average readmission costs, and probabilities for attendees and substituting the 
number of discharges for the predicted incidence (785,000), and the national 
average for readmission following AMI (19.9%).    
In comparison to transitional care programs in the literature, the BRIDGE 
program performs equally as well.  The transitional care programs developed by 
Coleman et al. (2006) and Jack et al. (2009) greatly improved the quality of 
transitional care between hospital and home, but with only modest savings.  The 
Care Transitions Intervention (Coleman et al., 2006) and Project Red (Jack et al., 
2009) both required tools, educators, and dedicated NPs.  The Care Transitions 
Intervention required NPs to provide in-home follow-up for 28 days after 
discharge along with telemanagement support. The average per-patient cost for 
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this intervention was $206 (reported cost of program divided by number of 
patients in the intervention group).  By emphasizing discharge teaching on an 
outpatient basis within 2-weeks of discharge, and providing telemanagement 
support, Krumholz et al. (2002) reported a much larger savings in readmission 
costs.  However, this population, unlike Coleman et al. and Jack et al. was limited 
to heart failure patients.  Naylor et al. also restricted their study to heart failure 
patients but required significantly more in-home follow-up over a 3-month period, 
and saved $4,845 per-patient.  Like the BRIDGE program, all of these programs 
were able to demonstrate a cost savings to varying degrees.  Yet despite their 
success and the inclusion of best and ideal practices, these programs have not 
realized national acceptance or implementation.  One possible flaw in these 
programs is patient ownership.  In each of these programs, a provider who may 
not be a member of the patient’s primary care or specialty care team follows the 
patient longitudinally.  In light of this issue, designing the BRIDGE intervention as 
a one-time visit and making the NPs an extension of the discharge team is novel.  
That the program is distinct and lacks “patient” competition may make it more 
user friendly by patients and providers while still providing significant cost 
savings. 
This analysis was performed with a societal perspective as is 
recommended for cost-effectiveness analyses (Weintraub, Cole, & Tooley, 
2002).  From this perspective, avoiding costly readmissions by implementing a 
less expensive program is a positive trade-off.  Yet, even when one considers the 
BRIDGE program from other perspectives, it continues to be an attractive option.  
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The patient perspective would require additional data on travel expenses, time, 
charges, and lost work, as well as social and quality of life indicators.  Despite 
these other factors, it is a reasonable hypothesis that, for most patients, a 
hospitalization is far more expensive and incurs far more consequences than a 
one-time outpatient visit.  From an insurer’s perspective, the reimbursement cost 
for a one-time clinic visit is far less than the cost of a hospitalization.   
The most controversial perspective is clearly from the institution’s point of 
view.  Traditionally, hospital revenue is generated by admissions.  Under this 
structure, there is a monetary incentive to readmit patients.  With the signing of 
the Patient Protection and Affordable Care Act of 2010, the Centers for Medicare 
and Medicaid Services will begin penalizing hospitals with excessive 30-day 
readmission rates for AMI, heart failure and pneumonia.  These fines may be 
exorbitant as they will be levied against inpatient Medicare beneficiary payments, 
and will increase from 1 percent to 3 percent by 2015 (Foster, 2010; Patient 
Protection and Affordable Care Act of 2010). Though this change is to take place 
in 2013, penalties will be assessed on data from the fiscal year 2012---thus 
creating a great sense of urgency to reduce hospital readmission now.  At the 
same time that these changes in reimbursement are to occur, a pilot program to 
evaluate a bundled payment structure encompassing hospital charges and post-
discharge care will be initiated.  This legislation provides strong motivation for 
hospitals to collaborate with payers to develop an infrastructure that will support 
the hospital-to-home transition of patient care in an effort to reduce system costs. 
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Limitations 
This study has several limitations, the most notable being that follow-up 
was initiated within 14-days of discharge.  At the onset of the BRIDGE program 
(2008), this was an acceptable standard of practice.  Today, however, 7 days is 
the ideal goal based on studies done in heart failure (Hernandez et al., 2010).  
Having the intervention at day 14 post-discharge and attempting to measure 
outcomes at 30-days was problematic.  In reality, only the two-week period after 
the BRIDGE visit was measured.  Readmissions and deaths prior to the 
scheduled appointment date were excluded.  When comparing those who were 
excluded for early adverse events to the study population, one significant 
difference stood out: patients with early adverse events had higher Charlson 
Comorbidity Scores.   The CCI for the study population (~ 4) was not significantly 
different between participant and nonparticipants.  The CCI for patients with early 
adverse events was significantly higher (> 5).  This difference translates to nearly 
a 35% increase risk of mortality in the first year (Charlson et al., 1987).  This 
supports other research that earlier follow-up is critical.  Ad hoc, a 60-day cost 
analysis was preformed.  This time period conservatively reflects the true 
outcomes of the BRIDGE intervention.  The median time-from discharge to 
follow-up with a cardiologist for participants is 59 days.  The median time for 
follow-up with a cardiologist for usual care was 31 days.  This 60-day analysis 
reflects only BRIDGE intervention against usual care that did receive care by 
their cardiologist 30 days earlier.  The difference in the readmission rate is 9.5% 
greater at 60-days than at 30-days post-discharge (National increase 8.6%; 
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Jencks et al., 2009).  The per-patient savings at 60-days was $7,562 with a 
program savings of $468,854 in avoided readmissions for patients discharged 
with an ACS event.  This savings is 53% greater than what was observed 30-
days post-discharge.  
 Another significant limitation of this study is that key inputs were obtained 
from the literature.  It is reassuring, given this limitation, that the results of the 
sensitivity analysis were robust to wide variations of model inputs.  The average 
cost of a cardiac hospitalization was varied from $6,890 (least benefit observed) 
to $55,116 (most benefit observed).  This generous range is meant to provide 
confidence over a number of unmeasured variables that could impact the model 
assumptions such as readmission diagnoses, length of stay, and geographic 
location.  As the cost of hospitalizations increase, it becomes even more 
desirable to avoid readmissions.  From both the per-patient and program 
perspective, there were consistently cost savings over a range of 25%-200% of 
the base case.  Cost of the BRIDGE program was similarly varied to account for 
differences in NP salary, benefits, costs of support staff, space, utilities, supplies, 
and geographic location that could occur.  BRIDGE cost had little impact on the 
outcome when varied from 25%-200% of the base case. 
 Another limitation of this study is that it was conducted via an 
observational registry and not a randomized controlled trial.  Patients chose 
whether or not to attend and the resulting groups were not necessarily 
equivalent.  Therefore, the results may not be generalizable.  However, it has 
been argued that results from well done observational studies may more closely 
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approximate usual care (Avorn, 2007).  Given the high adherence with evidence-
based therapies at the study hospital, this study may actually have a dual benefit.   
Ideally, it reflects typical care among patients who utilize this facility and the 
benefit of BRIDGE is in comparison to patients who are already receiving high 
quality evidence-based management.  Because the most critical input in this 
model is the difference in readmission rates between BRIDGE participants and 
those who received usual care, knowing that patients receiving usual care 
represent a well-cared-for cohort makes this a more conservative estimate of the 
program’s benefit. 
 Results of the one-way sensitivity analysis performed on the difference in 
readmission rates demonstrate the model’s sensitivity to this input.  The wider 
the gap between usual care and BRIDGE participants in readmissions, the more 
money is saved.  In the per-patient scenario, there was a cost savings over the 
entire range of 25%-200% of the base case--- even with a difference as small as 
4.53%.  The results for program savings were not as resilient.  The formula for 
calculating the programmatic savings required that the actual rates for each 
group be examined instead of examining the difference between the groups.  As 
the rate of readmission for patients with usual care approaches the rate of those 
participating in BRIDGE (narrowing the gap to 0 or performing better than 
BRIDGE), there are no longer avoided readmissions and, therefore, no savings.  
This is an expected finding.  If, usual care had lower readmission rates than the 
BRIDGE program, there would be no need for such a program.   
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Conclusion 
 This cost and benefit analysis suggests that referring patients to an NP-
driven one-time transitional care clinic after discharge for an ACS event provides 
a substantial cost savings in terms of avoidable hospital readmissions compared 
to program costs.  As health care policy continues to change with the rising cost 
of providing care, so does accountability.  These results further support the 
growing body of research demonstrating that transitional care not only helps 
patients navigate an overburdened healthcare system, but also does so with a 
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Summary and Findings 
 This research adds to the growing body of knowledge on transitional care 
and how a nurse practitioner (NP)-led model can improve patient care quality and 
outcomes.  Results of this study offer several insights for health care 
administrators and providers aiming to improve the continuity of care for patients 
during the hospital-to-home transition.  This chapter provides a summary of the 
overall study findings, limitations, and conclusions as they relate to the research 
questions posed, as well as implications for future research. 
 The purpose of this research was to explore three separate but related 
research questions pertaining to the transitional care of patients with acute 
coronary syndrome (ACS) who were referred to the Bridging the Discharge Gap 
Effectively (BRIDGE) program at the University of Michigan.  The Integrated 
Client-Focused Transitional Care Model and its four main constructs (patient, 
clinician, system, and outcomes) formed the theoretical framework guiding the 
study.  This model posits that for patients to achieve optimal outcomes during 
their hospital-to-home transition, patient-specific characteristics and behaviors 
must be balanced by the system’s environment and the skills and abilities of the 
clinicians operating within that environment.  Each of the three studies tested a 
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different aspect of the model and its interrelationship with the other constructs.  
The first study examined patients’ persistence rates to medications endorsed by 
the American Heart Association and the American College of Cardiology in 
secondary prevention of future ACS events.  The degree of persistence was thus 
a measure of patient-specific behavior that depended upon appropriate clinician 
prescribing and was deemed paramount to positive health outcomes.  The 
second study, consistent with other studies of transitional care, measured 
hospital readmission rates as an outcome of the transition process (Naylor, 
Aiken, Kurtzman, Olds, & Hirschman, 2011).  The third study then evaluated the 
system costs of providing a BRIDGE program in comparison to avoided hospital 
readmissions in patients receiving usual care. 
 Study one (Chapter 2) used a regression model to determine if there was 
a difference in six-month medication persistence rates (beta-adrenergic blocking 
agents [ß-blockers], angiotensin converting enzyme inhibitors [ACE-inhibitors] or 
angiotensin receptor blocking agents [ARBs] in patients intolerant to ACE-
inhibitors, aspirin, HMG-CoA reductase inhibitors [statins], and clopidogrel) 
following discharge from the hospital for an ACS event between patients who 
participated in the NP-delivered BRIDGE program and those who did not.  It was 
hypothesized that when compared to patients who had usual care, patients in the 
BRIDGE program would exhibit higher rates of medication persistence six 
months after discharge.  There were several interesting findings from the 
analysis.  First, data revealed that more patients discharged on ACE-Is attended 
their BRIDGE appointment than did patients prescribed any other medication.  
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The rationale for this finding is unclear given that there were no apparent 
demographic differences or disease severity differences between the 2 groups.  
One possible explanation for this may be related to clinician behavior.  That is to 
say, since 75.3% of patients received prescriptions for ACE-Is and only one-
quarter of patients did not, perhaps where ACE-Is were warranted clinicians were 
more inclined to stress the importance of early follow-up in the BRIDGE clinic.  
Second, overall medication persistence 6-months after discharge for any single 
agent was high for all study participants and there were no differences in 6-
month persistence rates between usual care and BRIDGE participants.  There 
were no cases where patients were taking zero medications.  Given the small 
sample size, little can be concluded about the persistence habits of patients 
prescribed 4 or 5-drug combined pharmacotherapy regimens.  While, a slightly 
higher percentage of patients who attended BRIDGE remained on a 5-drug 
regimen six months after discharge, further research and a larger sample are 
needed to determine if the intervention group really does have higher persistence 
and whether persistence is potentially provider driven.  Unfortunately only 4 of 
the 21 models tested were predictive of medication persistence at six-months:  ß-
blockers or ACE-inhibitors adjusted for either the CCI or GRACE Risk Score.  
However, these four models did explain between 22.9% and 53.1% of the 
variance in six-month medication persistence for the drug class being analyzed.  
Potentially with a larger sample size these models will demonstrate better 
discrimination. 
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 In study two (Chapter 3) readmission rates were calculated to determine if 
there was a difference in hospital readmissions following discharge between ACS 
patients who participated in the NP-delivered BRIDGE program and those who 
did not.  It was hypothesized that when compared with patients who had usual 
care, patients who participated in the BRIDGE program would have a lower 30-
day hospital readmission rate.  In fact, the NP-driven, single-dose, transitional 
care program was found to be an effective strategy to lower all-cause hospital 
readmissions for ACS patients out to 180-days post-discharge.  Even with 
adjustments for severity of illness and severity of event, patients who chose to 
attend their BRIDGE appointments fared better than patients with usual care.  
 The final study (Chapter 4) incorporated a cost model to determine costs 
associated with the BRIDGE program and the difference in costs associated with 
its use compared to nonuse (usual care) in hospital readmissions following 
discharge from the hospital for an ACS event.  It was hypothesized that 
compared with usual care, there would be a cost reduction for care associated 
with participation in the BRIDGE program.  Indeed, the results of the cost model 
support the BRIDGE program and highlight the potential savings in avoided 
hospital readmissions when compared to usual care.  The analysis demonstrated 
that the BRIDGE model reduced health care costs associated with readmissions 
in excess of operational costs.  On average, there was a per-patient savings of 
$4,944, which translated into an annual savings of $306,537 in avoided ACS 
readmission costs.   
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Limitations 
While the implications of this study in informing healthcare administrators 
and providers about the potential outcomes of transitional care are tremendous, 
the results must be considered in light of several limitations.  Perhaps most 
important is that this intervention takes place within a large academic medical 
center in Ann Arbor, Michigan.  As such, while results may offer valuable insight 
into a real-world settings (Avorn, 2007), they may not be generalizable outside of 
the study population.  Particularly pertinent in this study is that the rate of 
compliance with evidence-based standards for usual care is extremely high.   
Another concern is that this study lacks randomization and is at risk of 
selection bias in two ways.  First, the study represents patients who either chose 
to be treated at the UMHS or who were mandated by their health insurance to 
seek treatment here.  Second, all patients made a choice to attend the BRIDGE 
program.  Therefore, the between-group comparisons may be biased if 
individuals who chose to be seen differ in some as yet unmeasured manner from 
those who did not.  Because this was an anticipated limitation, specific follow-up 
was built into the abstraction phase, per clinic protocol, to contact patients who 
opted out by phone to determine their reason for not attending.   
 Other potential threats to internal validity included information bias and 
attribution bias.  Although a quality and audit system were in place to minimize 
the potential for information bias, it is difficult to estimate if this may have 
impacted the study.  Also, there may be an attribution bias in this study.  A crucial 
assumption of this model is that education about disease and management will 
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lead to better patient adherence to secondary preventions and medication 
persistence.  This assumption may not be true for all patients, and may vary by 
the style, education, and training of the NP providing care.  Outcomes observed 
may therefore be wrongfully attributed to BRIDGE, when in fact, they are due to 
some outside unmeasured variable, maturational effect or the Hawthorne effect. 
 Another limitation, given the use of an observational registry, is that data 
were collected retrospectively.  To calculate drug persistence, for example, 
patients with contraindications to study medications were excluded from the 
analysis.  However, if a patient had a troublesome effect or a contraindication to 
a medication that was not explicitly documented, the patient may have been 
misclassified as having lower medication persistence.  This error would result in 
an overestimation of BRIDGE’s potential to improve medication persistence 
(Mukherjee et al., 2004). 
 Lastly, the concept of persistence is itself a potential limitation of this 
study.  In this study, persistence was measured by self-report.  Despite evidence 
that self-reported persistence, at least in the short-term, is equitable to pill counts 
(Haynes et al., 1980; Yiannakopoulou et al., 2005) this may raise concern for 
those desiring a more substantive measure.  This is particularly salient given the 
strong association of poor outcomes with medication non-adherence among ACS 
patients (Gehi et al., 2007).  Hence, these results should not be taken out of 
context.  While persistence is an essential component of adherence, these 
results only reflect self-reported medication persistence six months post-
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discharge and do not offer any quantitative measure of medication adherence 
rates with a prescribed medication regimen.   
 Conclusion 
 As a nation, health care is of great concern.  Our population is growing 
older, living longer with more chronic disease (Centers for Disease Control and 
Prevention, 2011), and incurring greater care-related costs (Stanton, 2006).  As 
the health care system has grown in complexity, an unfortunate chasm has 
divided inpatient and outpatient care along the care continuum.  For patients with 
ACS, for example, the inability for or lag in follow-up with a care provider after 
hospital discharge often leads to increased readmissions or other complications. 
But as noted previously, there are a host of other reasons for hospital 
readmission following an ACS event beyond the lack of timely outpatient follow-
up.  Included among these are premature discharge, insufficient discharge 
education, poor patient comprehension (Greenwald & Jack, 2009), a shortage of 
cardiologists (Fye, 2004), and lack of adherence to the joint American Heart 
Association/American College of Cardiology secondary prevention guidelines 
(Eagle, Kline-Rogers, et al., 2004; Mehta et al., 2002).  Despite numerous care 
models aimed to address these issues, none have commanded strong enough 
support for widespread deployment (Jencks et al., 2009).  Current efforts are 
focusing on why this is so and what, if any programs might meet the complex 
needs of patients between hospital discharge and outpatient follow-up (American 
College of Cardiology, 2011; Brooten et al., 2002; Coleman et al., 2006; 
Greenwald & Jack, 2009; Naylor et al., 2004; Naylor et al., 1999; Phillips et al., 
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2004; Sinclair et al., 2005; Stewart et al., 1998).  Although heart failure is the 
most scrutinized diagnosis in this area, legislative changes promoting penalties 
on hospitals for excessive readmission rates have widened the scope of analysis 
to models of care for individuals with other diagnoses such as ACS and 
pneumonia.  Many of these models tested variations or combinations of 
enhanced discharge education, telephone follow-up, or in-home visits in 
increasing care quality (Coleman et al., 2006; Naylor et al., 2004; Sinclair et al., 
2005; Stewart et al., 1998).  Phillips et al. (2004) argued that such interventions 
could potentially lower hospital readmissions and costs as well if patients can 
successfully recover from their illness and avoid relapse.   
Adherence to standardized best-practice guidelines is one way to ensure 
that patients have the best opportunity for success in the transition between 
hospital discharge and follow-up.  The concept of adherence is prevalent in 
transitional literature, but surprisingly few measure it (Peikes, Chen, Schore, & 
Brown, 2009).  Further, no study has explicitly explored the concept of “dose” 
that is, how much transitional support is needed for a successful recovery. 
Indeed, most of what we know about dosage is more implied than quantified.  For 
example, studies that only emphasize discharge teaching may be considered to 
be low dose interventions while studies with multiple home visits might be higher 
dose.  No study has been able to specify the ideal amount of care needed, 
examined a single-dose model of care, or considered how dose requirements for 
transitional care may vary by patient characteristics and/or disease state.     
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 The University of Michigan Health System’s (UMHS) approach to 
managing the transitional care gap for patients with cardiovascular (CV) disease 
is Bridging the Discharge Gap Effectively (BRIDGE), a program designed to 
ensure that patients discharged after an ACS event have support through the 
hospital-to-home period. This ambulatory clinic is staffed by five independent, 
specialized, CV NPs, who function in collaboration with on-site cardiologists and 
who act as an extension of the in-hospital care team (Housholder & Norville, 
2009).  NPs in the BRIDGE clinic assess the clinical status of their patients, 
make therapeutic adjustments, provide education and make referrals 
(Housholder & Norville, 2009).  By offering this service to all CV patients within 
14 days of discharge, the UMHS is able to provide a safety-net for patients to 
avoid poor outcomes due to lack of care during the hand-off between inpatient 
and outpatient services. 
 This model could easily be replicated for other sites and other conditions.  
BRIDGE was created within an established practice, and therefore, no additional 
overhead costs were required.  Further, NPs are known for their abilities to 
develop therapeutic relationships while identifying the patient’s needs and 
providing patient, family, and caregiver education (Brown & Grimes, 1995; 
Horrocks et al., 2002; Naylor & Keating, 2008).  
Future Research 
  Future analyses utilizing a larger sample size are necessary for further 
evaluation of the BRIDGE program as it will allow detection of true differences 
between patients who receive transitional care and usual care.  Additionally, low 
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readmission rates in the intervention group (BRIDGE participants) prohibited 
developing a multivariate model for medication persistence.  A larger sample will 
thus facilitate development of regression models explaining medication 
persistence behavior and readmissions.  A larger sample is also needed to 
appreciate how this program effects racial, ethnic, and gender minorities, and if 
such a program may help to decrease CV disparities among and between 
different population cohorts.  Of note, this study is unique in that it has a higher 
percentage of female over male participants, although like many other studies, 
they are largely Caucasian. 
 Future research should also aim to better define the BRIDGE program 
within the context of transitional care and measure other appropriate outcomes 
for model development.  For example, both patient and provider surveys would 
be helpful to evaluate patient’s satisfaction with the BRIDGE program, and to 
appraise how a patient’s knowledge attitudes and beliefs related to ACS are 
effected by the program.  A provider survey could potentially identify barriers to 
BRIDGE utilization and offer alternative processes to facilitate transition.    
 Given the significant reductions in readmission and the value of the 
program from avoided readmissions, further research into the benefit of BRIDGE 
for other disease states is warranted.  While patients with ACS benefit from this 
one-time treatment, perhaps those with other conditions, such as heart failure, 
may not.  Similarly, it would be interesting to examine how specific diagnoses 
(i.e. depression) effect patient’s decisions to participate and the resulting 
outcomes.    
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 As other measures of outcomes should be evaluated, so should other 
measures of patient adherence.  As noted earlier, this study measures self-
reported medication persistence.  Future research employing a more quantitative 
measure of medication persistence and adherence, as well as an assessment of 
lifestyle modifications, would be of great value in further appraising the benefits 
of transitional care over usual care.   
 Finally, the BRIDGE program is an exemplar of the Integrated Client-
Focused Transitional Care Model.  Transitional care theory is by nature 
developmental.  That is to say that while older transition models are useful, they 
require expansion.  Transitional care is integrally joined to two diverse and 
evolving areas of health care (hospital or acute care and outpatient or ambulatory 
care).  As these aspects of healthcare mature and change, so must any 
conjoining transitional care model.  The Integrated Client-Focused Transitional 
Care Model incorporates new concepts in healthcare such as patient-centered 
care.  Within this model, the patient is the essential construct as patients are 
given more responsibility for their care.  Yet, the patient remains the critical 
element that all other forces in a team-approach must work to balance.  
Therefore, both the theoretical framework and the BRIDGE program require 
further validation of the theoretical underpinnings and analysis of measurable 
constructs.  BRIDGE, in particular, should be compared to other models including 
physician models and models that vary dosage.   
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Summary 
 Transitional care is a highly debated focus area today.  Many institutions 
and groups are working feverishly to design and implement their own models.  
While patients will reap the greatest rewards of improved hospital-to-home care, 
soon institutions may be severely penalized if the lack of transitional care results 
in excessive readmission rates.    
 The BRIDGE model is an appealing strategy for improving transitional 
care.  It is clear that many patients require early post-discharge education, 
medication counseling, and referrals beyond what was received at discharge. 
BRIDGE fulfils this need and has demonstrated initial success in reducing 30-day 
readmissions at a cost value.  Ultimately, BRIDGE capitalizes on available 
resources and successfully improves patient care quality that, in turn, may 
improve adherence to secondary prevention measures, lower readmission rates, 
and is cost appealing.  In conclusion, the BRIDGE model is a novel means to 
address transitional care and a practical method to address the vexing nation-




Agency for Healthcare Research and Quality. (2010). Hospital readmsisions 
research. Retrieved from http://www.ahrq.gov 
Akincigil, A., Bowblis, J., Levin, C., Jan, S., Patel, M., & Crystal, S. (2008). Long-
term adherence to evidence based secondary prevention therapies after 
acute myocardial infarction. Journal of general internal medicine, 23(2), 
115-121. doi: 10.1007/s11606-007-0351-9 
Albert, N. M. (2008). Improving Medication Adherence in Chronic Cardiovascular 
Disease. Critical Care Nurse, 28(5), 54-64.  
American College of Cardiology. (2011). Hospital to Home: Reducing 
readmissions. Improving transitions. Retrieved July 17, 2011, 2011, from 
http://www.h2hquality.org/Home/tabid/38/Default.aspx 
American Heart Association. (2009). Heart disease and stroke statistics-2009 
update. Dallas, Texas: American Heart Association. Retrieved from 
americanheart.org 
American Hospital Directory. (2011, 04/14/2011). Your best resource for hospital 
information and custom data services. Retrieved July 20, 2011, 2011, from 
www.ahd.com 
Anderson, J., Adams, C., Antman, E., Bridges…, C., Califf, R. M., Casey Jr, D. 
E., . . . Wright, R. S. (2011). 2011 ACCF/AHA Focused Update 
Incorporated Into the ACC/AHA 2007 Guidelines for the Management of 
Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction : A 
Report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. Circulation, 123, e426-
e579. doi: 10.1161/CIR.0b013e318212bb8b 
Antithrombotic Trialists' Collaboration. (2002). Collaborative meta-analysis of 
randomised trials of antiplatelet therapy for prevention of death, 
myocardial infarction, and stroke in high risk patients. BMJ, 324(7329), 71-
86. doi: 10.1136/bmj.324.7329.71 
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., 
Hochman, J. S., . . . Krumholz, H. M. (2004). ACC/AHA guidelines for the 
management of patients with ST-elevation myocardial infarction. Journal 
of the American College of Cardiology, 44(3), E1-E211. doi: 
10.1016/j.jacc.2004.07.014 
Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., 
Halasyamani, L. K., . . . JR. (2009). 2007 focused update of the ACC/AHA 
2004 guidelines for the management of patients with ST-elevation 
myocardial infarction. Journal of the American College of Cardiology, 
51(2), 210-247. doi: 10.1016/j.jacc.2007.10.001 
Arora, V., & Farnan, J. (2008). Care transitions for hospitalized patients. Medical 
Clinics of North America, 92, 315-324. doi: 10.1016/j.mcna.2007.11.002  
 140 
Avorn, J. (2007). In Defense of Pharmacoepidemiology-Embracing the Yin and 
Yang of Drug Research. New England Journal of Medicine, 357(22), 
2219-2221. doi: doi:10.1056/NEJMp0706892 
Benner, J., Glynn, R., Mogun, H., Neumann, P., Weinstein, M. C., & Avorn, J. 
(2002). Long-term persistence in use of statin therapy in elderly patients. 
Journal of the American Medical Association, 288(4), 455-461. doi: 
10.1001/jama.288.4.455 
Bodenheimer, T. (2008). Coordinating care--a perilous journey through the health 
care system. The New England Journal of Medicine, 358(10), 1064-1071.  
Bridges, W. (2004). Transitions: making sense of life's changes. Cambridge, MA: 
De Capo Press. 
Brindis, R., & Krumholz, H. M. (2010). President's Page: National Quality 
Initiatives Put ACC's Mission Into Action. Journal of the American College 
of Cardiology, 56(15), 1260-1262. doi: 10.1016/j.jacc.2010.09.004 
Brooten, D., Brown, L., Munro, B., York, R., Cohen, S. M., Roncoli, M., & 
Hollingsworth, A. (1988). Early discharge and specialist transitional care. 
Journal of Nursing Scholarship, 20(2), 64-68.  
Brooten, D., Naylor, M., York, R., Brown, L. P., Munro, B. H., Hollingsworth, A. 
O., . . . Youngblut, J. M. (2002). Lessons learned from testing the quality 
cost model of advanced practice nursing (APN) Transitional Care. Journal 
of Nursing Scholarship, 34(4), 369-375.  
Brown, S. A., & Grimes, D. E. (1995). A meta analysis of nurse practitioners and 
nurse midwives in primary care. Nursing Research, 44(6), 332-339.  
Burke, L. E., Dunbar-Jacob, J. M., & Hill, M. N. (1997). Compliance with 
cardiovascular disease prevention strategies: a review of the research. 
Annals of Behavioral Medicine, 19(3), 239-263. doi: 10.1007/BF02892289 
CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel 
versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 
348(9038), 1329-1339.  
Centers for Disease Control and Prevention. (2011). Healthy aging. Retrieved 
February 12, 2012, from 
http://www.cdc.gov/chronicdisease/resources/publications/AAG/aging.htm
#aag 
Charlson, M., Pompei, P., Ales, K., & MacKenzie, C. (1987). A new method of 
classifying prognostic comorbidity in longitudinal studies: development and 
validation. Journal of Chronic Diseases, 40(5), 373-383. doi: 
10.1016/0021-9681(87)90171-8 
Charlson, M., Szatrowski, T., Peterson, J., & Gold, J. (1994). Validation of a 
combined comorbidity index. Journal of Clinical Epidemiology, 47(11), 
1245-1251. doi: 10.1016/0895-4356(94)90129-5 
Chick, N., & Meleis, A. I. (1986). Transitions: a nursing concern. In P. L. Chinn 
(Ed.), Nursing Research Methodology (pp. 237-257). Boulder, CO: Aspen 
Publication. 
Chiu, W., & Newcomer, R. (2007). A systematic review of nurse-assisted case 
management to improve hospital discharge transition outcomes for the 
 141 
elderly. Professional Case Management, 12(6), 330-336. doi: 
10.1097/01.PCAMA.0000300406.15572.e2 
Choudhry, N., Avorn, J., Antman, E., Schneeweiss, S., & Shrank, W. H. (2007). 
Should Patients Receive Secondary Prevention Medications For Free 
After A Myocardial Infarction? An Economic Analysis. Health Affairs, 
26(1), 186-194. doi: 10.1377/hlthaff.26.1.186  
Choudhry, N., Patrick, A., Antman, E., Avorn, J., & Shrank, W. H. (2008). Cost-
effectiveness of providing full drug coverage to increase medication 
adherence in post myocardial infarction medicare beneficiaries. 
Circulation, 117, 1261-1268. doi: 
10.1161/CIRCULATIONAHA.107.735605 
Choudhry, N., & Winkelmayer, W. (2008). Medication adherence after myocardial 
infarction: a long way left to go. Journal of general internal medicine, 
23(2), 216-218.  
Coleman, E., Parry, C., Chalmers, S., & Min, S. (2006). The care transitions 
intervention: results of a randomized controlled trial. Archives of Internal 
Medicine, 166(17), 1822-1828.  
Conrad, D. A., & Christianson, J. B. (2004). Penetrating the &quot;Black 
Box&quot;: Financial Incentives for Enhancing the Quality of Physician 
Services. Medical Care Research and Review, 61(3 suppl), 37S-68S. doi: 
10.1177/1077558704266770 
Cramer, J., Roy, A., Burrell, A., & Fairchild, C. (2008). Medication compliance 
and persistence: terminology and definitions. Value in Health, 11(1), 44-
47. doi: 10.1111/j.1524-4733.2007.00213.x 
Cumbler, E., Carter, J., & Kutner, J. (2008). Failure at the transition of care: 
challenges in the discharge of the vulnerable elderly patient. Journal of 
Hospital Medicine, 3(4), 349-352. doi: 10.1002/jhm.304 
Davidson, P., Dracup, K., Phillips, J., Padilla, G., & Daly, J. (2007). Maintaining 
hope in transition: a theoretical framework to guide interventions for 
people with heart failure. Journal of Cardiovascular Nursing, 22(1), 58-64.  
Dhalla, I. A., Smith, M. A., Choudhry, N. K., & Denburg, A. E. (2009). Costs and 
Benefits of Free Medications after Myocardial Infarction. Healthcare 
Policy, 5(2), 68-86. doi: PMC2805141 
DiMatteo, M. (2004). Variations in patients adherence to medical 
recommendations: A quantitative review of 50 years of research. Medical 
Care, 42(3), 200-209. doi: 10.1097/01.mlr.0000114908.90348. 
Donabedian, A. (1966). Evaluating the quality of medical care. The Milbank 
Memorial Fund Quarterly, 44(3), 166-206.  
Eagle, K., Kline-Rogers, E., Goodman, S., Gurfinkel, E. P., Avezum, A., Flather, 
M. D., . . . Steg, P. G. (2004). Adherence to evidence-based therapies 
after discharge for acute coronary syndromes: An Ongoing Prospective, 
Observational Study. The American Journal of Medicine, 117(2), 73-81. 
doi: 10.1016/j.amjmed.2003.12.041 
Eagle, K., Lim, M., Dabbous, O., Pieper, K., Goldberg, R. J., Van deWerf, F., . . . 
Fox, K. A. A. (2004). A validated prediction model for all forms of acute 
coronary syndrome: estimating the risk of 6-month post-discharge death in 
 142 
an International registry. Journal of the American Medical Association, 
291(22), 2727-2733. doi: 10.1001/jama.291.22.2727 
Elbarouni, B., Goodman, S., Yan, R., Welsh, R., Kornder, J. M., DeYoung, J. P., . 
. . Yan, A. T. (2009). Validation of the Global Registry of Acute Coronary 
Event (GRACE) risk score for in-hospital mortality in patients with acute 
myocardial coronary syndrome in Canada. American Heart Journal, 
158(3), 392-399. doi: 10.1016/j.ahj.2009.06.010 
Ellerbeck, E. F., Jencks, S. F., Radford, M. J., Timothy, F., Craig, A. S., Gold, J. 
A., . . . Vogel, R. A. (1995). Quality of care for Medicare patients with 
acute myocardial infarction: a four-state pilot study from the cooperative 
cardiovascular project. Journal of the American Medical Association, 
273(19), 1509-1514. doi: 10.1001/jama.1995.03520430045037 
Fishbein, M., & Ajzen, I. (1975). Belief, attitude, intention, and behavior: An 
introduction to theory and research. Reading, MA: Addison-Wesley. 
Fisher, J., Amico, K., Fisher, W., & Harman, J. (2008). The information-
motivation-behavioral skills model of antiretroviral adherence and Its 
Applications. Current HIV/AIDS Reports, 5(4), 193-203. doi: 
10.1007/s11904-008-0028-y 
Fisher, J. D., & Fisher, W. A. (2002). The Information-Motivation-Behavioral Skills 
Model. In R. J. DiClemente, R. A. Crosby & M. C. Kegler (Eds.), Emerging 
Theories in Health Promotion Practice and Research (pp. 40-70). San 
Fransisco, CA: Jossey-Bass. 
Fisher, W. A., & Fisher, J. D. (2003). The Information-Motivation-Behavioral Skills 
Model: a general social psychological approach to understanding and 
promoting health behavior. In H. Tennen & G. Affleck (Eds.), Social 
Psychological Foundations of Helath and Illness (pp. 82-106). Malden, 
MA: Blackwell Publishing LTD. 
Foster, D. (2010). Healthcare Reform: Pending Changes to Reimbursement for 
30-Day Readmissions. Thomson Reuters.  
Fye, W. B. (2004). Cardiology workforce: a shortage, not a surplus. Health 
Affairs, Jan-July (Supp Web Exclusives), W4-43-59. doi: 
10.1377/hlthaff.W4.64 
Gehi, A. K., Ali, S., Na, B., & Whooley, M. A. (2007). Self-reported medication 
adherence and cardiovascular events in patients with stable coronary 
heart disease: the heart and soul study. Archives of Internal Medicine, 
167(16), 1798-1803.  
Granger, C., Goldberg, R., Dabbous, O., Pieper, K., Eagle, K., Cannon, C., . . . 
Flather, M. (2003). Predictors of hospital mortality in the global registry of 
acute coronary events. Archives of Internal Medicine, 163(19), 2345-2353.  
Greenwald, J., & Jack, B. (2009). Preventing the preventable: reducing 
rehospitalizations through coordinated, patient-centered discharge 
processes. Professional Case Management, 14(3), 135.  
Harrison, M. B., Browne, G. B., Roberts, J., Tugwell, P., Gafni, A., & Graham, I. 
D. (2002). Quality of Life of Individuals With Heart Failure: A Randomized 
Trial of the Effectiveness of Two Models of Hospital-to-Home Transition. 
Medical Care, 40(4), 271-282.  
 143 
Haynes, R., Taylor, D., Sackett, D., Gibson, E., BERNHOLZ, C. D., & 
MUKHERJEE, J. (1980). Can simple clinical measurements detect patient 
noncompliance? Hypertension, 2, 757-764.  
Haynes, R. B., McKibbon, K. A., & Kanani, R. (1996). Systematic review of 
randomised trials of interventions to assist patients to follow prescriptions 
for medications. The Lancet, 348(9024), 383-386. doi: 10.1016/S0140-
6736(96)01073-2 
Hernandez, A. F., Greiner, M. A., Fonarow, G. C., Hammill, B. G., Heidenreich, 
P. A., Yancy, C. W., . . . Curtis, L. H. (2010). Relationship Between Early 
Physician Follow-up and 30-Day Readmission Among Medicare 
Beneficiaries Hospitalized for Heart Failure. JAMA: The Journal of the 
American Medical Association, 303(17), 1716-1722. doi: 
10.1001/jama.2010.533 
Hippisley-Cox, J., & Coupland, C. (2005). Effect of combinations of drugs on all 
cause mortality in patients with ischaemic heart disease: nested case-
control analysis. British Medical Journal, 330(7499), 1059-1063. doi: 
10.1136/bmj.330.7499.1059  
Ho, P., Spertus, J., Masoudi, F., & Reid, K. (2006). Impact of medication therapy 
discontinuation on mortality after myocardial infarction. Archives of Internal 
Medicine …, 166, 1842-1847.  
Holzemer, W., & Reilly, C. (1995). Variables, variability, and variations research: 
implications for medical informatics. Journal of the American Medical 
Association, 2(3), 183-190. doi: 10.1136/jamia.1995.95338871 
Horrocks, S., Anderson, E., & Sallisbury, C. (2002). Systematic review of whether 
nurse practitioners in primary care can provide equivalent care to doctors. 
British Medical Journal, 324, 819-823. doi: 10.1136/bmj.324.7341.819 
Housholder, S., & Norville, J. (2009). Bridge clinic background. unpublished 
manuscript. University of Michigan. Ann Arbor.  
Jack, B., Chetty, V., Anthony, D., Greenwald, J. L., Sanchez, G. M., Johnson, A. 
E., . . . Culpepper, L. (2009). A reengineered hospital discharge program 
to decrease rehospitalization. Annals of Internal Medicine, 150, 178-187.  
Jacob, L., & Poletick, E. (2008). Systematic review: predictors of successful 
transition to community- based care for adults with chronic care needs. 
Care Management Journals, 9(4), 154-165. doi: 10.1891/1521-
0987.9.4.154 
Jencks, S., Williams, M., & Coleman, E. (2009). Rehospitalizations among 
patients in the Medicare fee-for-service program. The New England 
Journal of Medicine, 360(14), 1418-1428.  
Jerant, A., DiMatteo, R., Arnsten, J., Moore-Hill, M., & Franks, P. (2008). Self-
report adherence measures in chronic illness: retest reliability and 
predictive validity. Medical care, 46(11), 1134-1139.  
Jha, A., Orav, E., & Epstein, A. (2009). Public Reporting of Discharge Planning 
and Rates of Readmissions. New England Journal of Medicine, 261(27), 
2637-2645.  
Kind, A. J. H., Smith, M. A., Frytak, J. R., & Finch, M. D. (2007). Bouncing back: 
patterns and predictors of complicated transitions 30 days after 
 144 
hospitalization for acute ischemic stroke. [Comparative Study]. Journal of 
the American Geriatrics Society, 55(3), 365-373. doi: 10.1111/j.1532-
5415.2007.01091.x 
Krumholz, H., Amatruda, J., Smith, G., Mattera, J., Roumanis, S., Radford, M., . . 
. Vaccarino, V. (2002). Randomized trial of an education and support 
intervention to preventreadmission of patients with heart failure. Journal of 
the American College of Cardiology, 39(1), 83-89. doi: 10.1016/S0735-
1097(01)01699-0 
Krumholz, H., Merrill, A., Schone, E., Schreiner, G. C., Chen, J., Bradley, E. H., . 
. . Drye, E. E. (2009). Patterns of hospital performance in acute 
myocardial infarction and heart failure 30-day mortality and readmission. 
Circulation: Cardiovascular Quality and Outcomes, 2, 407-413. doi: 
10.1161/CIRCOUTCOMES.109.883256 
Manning, W. G., Fryback, D. G., & Weinstein, M. C. (1996). Reflecting 
uncertainty in cost-effestiveness analysis. In M. R. Gold, L. B. Russel, J. 
E. Siegel & M. C. Weinstein (Eds.), Cost-effectiveness in health and 
medicine. New York: Oxford University Press. 
Margulis, A. V., Choudhry, N. K., Dormuth, C. R., & Schneeweiss, S. (2011). 
Variation in initiating secondary prevention after myocardial infarction by 
hospitals and physicians, 1997 through 2004. Pharmacoepidemiology and 
drug safety, 20(10), 1088-1097. doi: 10.1002/pds.2144 
McLaughlin, T. J., Soumerai, S. B., Willison, D. J., Gurwitz, J. H., Borbas, C., 
Guadagnoli, E., . . . Gobel, F. (1996). Adherence to national guidelines for 
drug treatment of suspected acute myocardial infarction: evidence for 
undertreatment in women and the elderly. Archives of Internal Medicine, 
156(7), 799-805. doi: 10.1001/archinte.1996.00440070131015 
Mehta, R., Montoye, C., Faul, J., Nagle, D., Kure, J., Raj, E., . . . Changezi, H. 
(2004). Enhancing quality of care for acute myocardial infarction: shifting 
the focus of improvement from key indicators to process of care and tool 
use The American College of Cardiology Acute Myocardial Infarction 
Guidelines Applied in Practice Project in Michigan: Flint and Saginaw 
Expansion. Journal of the American College of Cardiology, 43(12), 2166-
2173.  
Mehta, R., Montoye, C., Gallogly, M., Baker, P., Blount, A., Faul, J., . . . Eagle, K. 
A. (2002). Improving quality of care for acute myocardial infarction: The 
Guidelines Applied in Practice (GAP) Initiative. Journal of the American 
Medical Association, 287(10), 1269-1276. doi: 10.1001/jama.287.10.1269 
Meleis, A. I., Sawyer, L. M., Im, E. O., Hilfinger Messias, D. K., & Schumacher, K. 
(2000). Experiencing transitions: An emerging middle range theory. 
Advances in Nursing Science, 23(1), 12-28.  
Mitchell, P., Ferketich, S., & Jennings, B. (1998). Quality health outcomes model. 
Image: Journal of Nursing Scholarship, 30(1), 43-46.  
Mitchell, P. H., & Lang, N. (2004). Framing the problem of measuring and 
improving healthcare quality: has the quality health outcomes model been 
useful? Medical Care, 42(2 suppl), II-4-II-11. doi: 
10.1097/01.mlr.0000109122.92479.fe 
 145 
Mukherjee, D., Fang, J., Chetcuti, S., Moscucci…, M., Kline-Rogers, E., & Eagle, 
K. A. (2004). Impact of combination evidence-based medical therapy on 
mortality in patients with acute coronary syndromes. Circulation, 109, 745-
749. doi: 10.1161/01.CIR.0000112577.69066.CB 
National Cholesterol Education Program. (2002). Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) Final Report. Circulation, 106(25), 3143.  
Naylor, M., Aiken, L., Kurtzman, E., Olds, D., & Hirschman, K. (2011). The 
Importance Of Transitional Care In Achieving Health Reform. Health 
Affairs, 30(4), 746-754. doi: 10.1377/hlthaff.2011.0041 
Naylor, M., Brooten, D., Campbell, R., Maislin, G., McCauley, K. M., & Schwartz, 
J. S. (2004). Transitional care of older adults hospitalized with heart 
failure: a randomized, controlled trial. Journal of the American Geriatrics 
Society, 52, 675-684. doi: 0.1111/j.1532-5415.2004.52202.x 
Naylor, M., Brooten, D., Jones, R., Lavizzo-Mourey, R., Meze, M., & Pauly, M. 
(1994). Comprehensive Discharge Planning for the Hospitalized Elderly. 
Annals of internal medicine, 120(12), 999-1006.  
Naylor, M., & Keating, S. (2008). Transitional Care. AJN The American Journal of 
Nursing, 108(9), 65-73. doi: 10.1097/01.NAJ.0000336420.34946.3a 
Naylor, M. D., Brooten, D., Campbell, R., Jacobsen, B. S., Mezey, M. D., Pauly, 
M. V., & Schwartz, J. S. (1999). Comprehensive Discharge Planning and 
Home Follow-up of Hospitalized Elders: A Randomized Clinical Trial. 
Journal of the American Medical Association, 281(7), 613-620. doi: 
10.1001/jama.281.7.613 
Needham, D., Scales, D., Laupacis, A., & Pronovost, P. (2005). A systematic 
review of the Charlson comorbidity index using Canadian administrative 
databases: a perspective on risk adjustment in critical care research. 
Journal of Critical Care, 20(1), 12-19. doi: 10.1016/j.jcrc.2004.09.007 
Newby, L., Eisenstein, E., Califf, R., Thompson, T., Nelson, C., Peterson, E., . . . 
Topol, E. (2000). Cost effectiveness of early discharge after 
uncomplicated acute myocardial infarction. The New England Journal of 
Medicine, 342(11), 749-755.  
Newby, L., LaPointe, A., Nancy, M., & Chen, A. (2006). Long-term adherence to 
evidence-based secondary prevention therapies in coronary artery 
disease. Circulation, 113, 203-212. doi: 
10.1161/CIRCULATIONAHA.105.505636 
Orszag Testimony, President's Fiscal Year 2010 Budget, U.S. House of 
Representatives, 111th Cong Sess. 11 (2009). 
Patient Protection and Affordable Care Act of 2010, & Pub. L. No. 111-148, 124 
Stat. 119. (2010). 
Pender, N. J., Murdaugh, C. L., & Parsons, M. A. (2006). Individual models to 
promote health Health promotion in nursing practice. Upper Saddle River, 
NJ: Pearson, Prentice Hall. 
Phillips, C., Wright, S., Kern, D., Singa, R., Shepperd, S., & Rubin, H. R. (2004). 
Comprehensive discharge planning with postdischarge support for older 
 146 
patients with with congestive heart failure: a meta-analysis. Journal of the 
American Medical Association, 291(11), 1358-1367. doi: 
10.1001/jama.291.11.1358 
Project Red [Re-engineered Discharge]. (2011). Retrieved August 4, 2011, 2011, 
from http://www.jcrinc.com/AHRQ-Project-Red/ 
Ramsay, G., Podogrodzka, M., McClure, C., & Fox, K. (2007). Risk prediction in 
patients presenting with suspected cardiac pain: the GRACE and TIMI risk 
scores versus clinical evaluation. QJM, 100(1), 11-18. doi: 
10.1093/qjmed/hcl133  
Ramsay, S., Whincup, P., Lawlor, D., Papacosta, O., Lennon, L. T., Thomas, M. 
C., . . . Morris, R. W. (2006). Secondary prevention of coronary heart 
disease in older patients after the national service framework: population 
based study. British Medical Journal, 332, 144-145. doi: 
10.1136/bmj.38704.770127.BE  
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. 
M., . . . Wylie-Rosett, J. (2011). Heart disease and stroke statistics--2011 
update: A report from the American Heart Association. Circulation, 123(4), 
e18-e209.  
Rosamond, W., Flegal, K., Friday, G., Furie, K., Go, A. S., Greenlund, K., . . . 
Hong, Y. (2007). Heart disease and stroke statistics--2007 update: a 
report from the American Heart Association statistics committee and 
stroke statistics subcommittee. Circulation, 115, e69-e171. doi: 
10.1161/CIRCULATIONAHA.106.179918 
Rosenstock, I. M. (1974). Historical origins of the health belief model. Health 
Education Monographs, 2(4), 328-335.  
Schumacher, K., & Meleis, A. I. (1994). Transitions: a central concept in nursing. 
Journal Of Nursing Scholarship, 26(2), 119-127.  
Simpson, E., Beck, C., Richard, H., Eisenberg, M. J., & Pilote, L. (2003). Drug 
prescriptions after acute myocardial infarction: Dosage, compliance, and 
persistence. American Heart Journal, 145(3), 438-444. doi: 
10.1067/mhj.2003.143 
Sinclair, A., Conroy, S., Davies, M., & Bayer, A. (2005). Post-discharge home-
based support for older cardiac patients: a randomised controlled trial. 
Age and Ageing, 34, 338-343. doi: 10.1093/ageing/afi116 
Smith Jr, S., Allen, J., Blair, S., Bonow…, R., Brass, L. M., Fonarow, G. C., . . . 
Taubert, M. A. P. a. A. (2006). AHA/ACC guidelines for secondary 
prevention for patients with coronary and other atherosclerotic vascular 
disease: 2006 update: endorsed by the National Heart, …. Circulation, 
113, 2363-2372. doi: 10.1161/CIRCULATIONAHA.106.174516 
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., 
Franklin, B. A., . . . Taubert, K. A. (2011). AHA/ACCF Secondary 
Prevention and Risk Reduction Therapy for Patients With Coronary and 
Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From 
the American Heart Association and American College of Cardiology 
Foundation. Circulation, 124(22), 2458-2473. doi: 
10.1161/CIR.0b013e318235eb4d 
 147 
Sokol, M., McGuigan, K., Verbrugge, R., & Epstein, R. (2005). Impact of 
medication adherence on hospitalization risk and healthcare cost. Medical 
care, 43(6), 521-530.  
Spencer, F., Lessard, D., Gore, J., Yarzebski, J., & Goldberg, R. (2004). 
Declining length of hospital stay for acute myocardial infarction and 
postdischarge outcomes: a community-wide perspective. Archives of 
Internal Medicine, 164(7), 733-740.  
Speroff, T., Miles, P., & Mathews, B. (1998). Improving health care, Part 5: 
Applying the Dartmouth clinical improvement model to community health. 
The Joint Commission Journal on Quality Improvement, 24(12), 679.  
Stanton, M. (2006). The high concentration of U.S. healthcare expenditures. 
(AHRQ Publication No. 06-0060). Rockville, MD: Agency for Healthcare 
Research and Quality. Retrieved from 
http://www.ahrq.gov/research/ria19/expendria.htm. 
Stewart, S., & Horowitz, J. (2002). Detecting early clinical deterioration in chronic 
heart failure patients post-acute hospitalisation—a critical component of 
multidisciplinary, home-based intervention? European Journal of Heart 
Failure, 4(3), 345-351.  
Stewart, S., Pearson, S., Luke, C., & Horowitz, J. (1998). Effects of home-based 
intervention on unplanned readmissions and out-of-hospital deaths. 
Journal of the American Geriatrics Society, 46(2), 174-180.  
Wald, N. J., & Law, M. (2003). A strategy to reduce cardiovascular disease by 
more than 80%. British Medical Journal, 326(7404), 1419-1423.  
Walker, L. O., & Avant, K. C. (2005). Theory Synthesis (4th ed.). Upper Saddle 
River, New Jersey: Pearson Education, Inc. 
Warner, K. E., & Luce, B. R. (1982). Introduction to cost-benefit and cost-
effectiveness analysis Cost-benefit and cost-effectiveness analysis in 
health care: principles, practice, and potential. Ann Arbor, MI: Health 
Administration Press. 
Weintraub, W., Cole, J., & Tooley, J. (2002). Cost and cost-effectiveness studies 
in heart failure research. American Heart Journal, 143(4), 565-576. doi: 
http://dx.doi.org.proxy.lib.umich.edu/10.1067/mhj.2002.120965 
Weiss, M. E., Piacentine, L. B., Lokken, L., Ancona, J., Archer, J., Gresser, S., . . 
. Vega-Stromberg, T. (2007). Perceived readiness for hospital discharge in 
dult medical-surgical patients. Clinical Nure Specialist, 21(1), 31-42.  
Wilson, P. W. F., D'Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & 
Kannel, W. B. (1998). Prediction of coronary heart disease using risk 
factor categories. Circulation, 97(18), 1837-1847. doi: 
10.1161/01.CIR.97.18.1837 
World Health Organization. (2010). Adherence to long-term therapies: evidence 
for action. 1-209.  
Yiannakopoulou, E., Papadopulos, J., Cokkinos, D. K., & Mountokalakis, T. D. 
(2005). Adherence to antihypertensive treatment: a critical factor for blood 
pressure control. Journal of ….  
Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., & Fox, K. K. 
(2001). Effects of clopidogrel in addition to aspirin in patients with acute 
 148 
coronary syndromes without ST-segment elevation. [Clinical Trial]. The 
New England Journal of Medicine, 345(7), 494-502. doi: 
10.1056/NEJMoa010746 
 
 
